Соединение, имеющее кристаллическую структуру типа перовскита АВХ3(варианты)

Группа изобретений принадлежит к области энергетических соединений, и в частности относится к вариантам соединений, имеющих кристаллическую структуру типа перовскита ABX3, которые могут использоваться как энергетический материал. Компонент А в соединении по первому варианту реализации представляет собой, по меньшей мере, один двухвалентный катион азотсодержащего органического соединения; компонент В в соединении представляет собой NH4+; компонент X в соединении представляет собой, по меньшей мере, один одновалентный анион, выбранный из ClO4-, BrO4-, IO4-, ONC-, NO3-и N(NO2)2-. Соединение, имеющее кристаллическую структуру типа перовскита АВХ3, по второму способу реализации получено добавлением компонента А, компонента В и компонента X в жидкую реакционную систему в любом порядке для реакции. Компонент А представляет собой азотсодержащее органическое соединение, способное образовать двухвалентный катион в жидкой реакционной системе; компонент В содержит катион и катион представляет собой ...

ПРИМЕНЕНИЕ СОЕДИНЕНИЙ В КАЧЕСТВЕ ЭНЕРГЕТИЧЕСКИХ МАТЕРИАЛОВ

MITTEL ZUR REGULIERUNG DES PFLANZENWACHSTUMS

Production of carboxylic acids

A process for the production of acetic acid by the liquid phase oxidation of propylene with O2 in an inert solvent (especially in a polyacyl ester such as propylene glycol diacetate) is characterized by (a) directing the product effluent to a combined zone comprising a flasher and a stripper at successively lower pressures to give an overhead of acetic acid + low boilers and bottoms of solvent + residue; (b) passing said overhead to condensers from which uncondensed gases pass to an absorber into which said bottoms also pass to absorb propylene and propane; removing inert gases from the absorber while feeding the bottoms stream therefrom back to the reactor; (c) adjusting reaction conditions such that the residue concentration in the reactor is maintained constant by balancing residue oxidized against residue formed; (d) feeding a combined liquid stream from the condensers to a primary products splitter from which propylene and propane are removed overhead to a splitter wherein the propane ...

Process for preparing a piperazine salt of 1,2 diphenyl-4n-butyl-3,5 dioxo-pyrazolidine

... 1,142,545. A piperazine salt. SOCIETE D'ETUDES ET DE REALISATIONS SCIENTIFIQUES SERESCI. 7 July, 1967 [9 May, 1967], No. 31384/67. Heading C2C. The piperazine salt of 1,2-diphenyl-4-butyl- 3,5-dioxopyrazolidine is prepared by dissolving piperazine and 1,2- diphenyl - 4 - butyl - 3,5 - dioxopyrazolidine in a solvent in which the salt is also soluble and then adding a solvent in which the salt is insoluble. Suitable acetone or methanol are used in the first step and hexane or ether is used in the second step and the reaction is carried out at about 30‹ C. An excess of piperazine can be used.

Compounds

Pharmaceutical preparations for topical application which contain salts of alkanecarboxylic acids, novel carboxlic acid salts and the production thereof

Pharmaceutical preparations for topical application contain salts of alkanecarboxylic acids, in particular compounds of the formula wherein R1 is a group of the formula wherein X1 and X2 are hydrogen and X3 is isobutyl or X1 and X3 are hydrogen and X2 is benzoyl, or X1 is hydrogen, X2 is chlorine, and X3 is 3-pyrrolin-1-yl, or X1 is hydrogen, X2 is a group of the formula -CH = CH-C(OCH3) = CH-X4, and X3 together with X4 are a bond, and R2 is methyl, or X2 and X3 are hydrogen and X1 is 2,6-dichloro- anilino, and R2 is hydrogen, or R1 is a group of the formula wherein X5 is the common bond with the methine group in formula I, X6 and X7 are hydrogen, X8 is p- methylbenzoyl, Y is a nitrogen atom, and X9 is a methyl group, or X5 is a methyl group, X6 is a common bond with the methine group in formula I, X7 is a group of the formula -CH = C(OCH3)-CH = CH-X10, X8 together with X10 are a bond, Y is a nitrogen atom and X9 is p- chlorobenzoyl, or X5 is a methyl group, X6 is ...

CARBOXYLIC ACID SALTS

Process for the preparation of a salicylate of a base of the morpholine series

Salicylates of morpholine and N-alkyl and N-aryl substitution derivatives thereof are made by reacting equimolecular quantities of the base with salicylic acid with or without a solvent for at least one of the reagents, or by interaction of a salt of the base and a salt of salicylic acid. Solvents specified are toluene, xylene, petroleum ether and ethyl ether which dissolve morpholine and salicylic acid but not morpholine salicylate; chlorinated organic solvents such as carbon tetrachloride, trichloroethylene and chlorobenzene which dissolves morpholine and salicylic acid (slightly) but not the salicylate; and also methanol, ethanol, n-propanol, iso-propanol, amyl alcohols, butyl alcohols, octyl alcohols, benzyl alcohols, ethyl acetate, anisol, acetone, benzene, nitrobenzene, chloroform and butyl bromide, in which both reagents and product are soluble. When the reaction between the base and the acid are carried out in aqueous solution the salicylate may be extracted from the product by ...

Piperazine adipate

Piperazine adipate is prepared by reacting piperazine in admixture with substantial amounts of other nitrogenous bases with adipic acid and separating piperazine adipate in relatively pure form from the reaction product by elution with an unsubstituted aliphatic alcohol containing 1 to 5 carbon atoms, the adipates of the other nitrogenous bases being dissolved while piperazine adipate remains undissolved. The reaction between the piperazine containing nitrogenous base mixture and the adipic acid may be carried out in the alcohol and the piperazine adipate thereby precipitated directly therefrom. Alternatively the reaction may be carried out in aqueous medium with subsequent evaporation of the solution to dryness and elution with the alcohol. Alcohols referred to are methanol, ethanol, industrial methylated spirit, n- and iso-propanol and n-butanol, Examples, including regeneration of piperazine from piperazine adipate by treatment of a slurry of the latter in acetone with potassium hydroxide ...

METHOD OF PRODUCING MORPHOLINE COMPOUND

... 1492359 Preparing morpholines TEXACO DEVELOPMENT CORP 5 May 1976 [2 June 1975] 18423/76 Heading C2C Morpholine compounds where each R is independently hydrogen or alkyl, and R1 is hydrogen or optionally substituted alkyl or aryl, are made by heating a compound HO.CKH.CR 2 .O.CR 2 .CRH.OH to 250-350‹ C. under sufficient pressure to maintain the starting material end product substantially in the liquid phase, in the presence of a phosphorus-containing compound.

TRYPTOPHAN DERIVATIVES HAVING AN INCREASED EFFECT ON THE CENTRAL NERVOUS SYSTEM

... 1529340 Tryptophan derivatives LA COOPERATION PHARMACEUTIQUE FRANCAISE 15 Dec 1975 [23 Dec 1974] 51324/75 Heading C2C Novel compounds I in substantially pure form (R is acetyl; M is Li or an alkaline earth metal of valency n, morpholinium or monoethanolammonium; n is 1 or 2) in the racemic DL or the optically active L(+) form are prepared by conventional salt formation from N-acetyltryptophan. N-acetyl-tryptophan is prepared by acetylation of tryptophan. Pharmaceutical compositions for oral, local or parenteral administration comprise a compound I together with a diluent and/or carrier other than a calcium compound. The compounds I are CNS active and some are antiulcer agents.

PARACETAMOL DERIVATIVES

... 1514225 Salts of paracetamol BOTTU 16 June 1975 [18 July 1974] 25554/75 Heading C2C The invention comprises piperazine salts of paracetamol of the formula wherein R 1 and R 2 each are H or C 1-4 alkyl and the preparation by reacting solutions of paracetamol with solutions of the appropriate piperazines. Pharmaceutical compositions, suitable for oral or parenteral administration, contain the above salts and pharmaceutically acceptable carriers or diluents.

SYNERGISTIC COMPOSITIONS

SYNERGISTIC COMPOSITIONS

SYNERGISTIC COMPOSITIONS

New derivatives of aliphatic acids phényl, their preparation, their application like drugs, and the compositions containing them.

New metal salts of mixed acids dithiocarbamic, their preparation and their application like fungicides.

Products weedkillers contain, as active matters, of substituted phénoxy-alkanes or the related compounds

PROCEDURE FOR the PRODUCTION OF NEW SALTS 2 - (2,6-DICHLORANILINO) - PHENYLESSIGSAEURE, THAT

PROCEDURE FOR THE PRODUCTION OF ETHYL AMINES

PROCEDURE FOR CONTINUOUS DISTILLATIVES ISOLATING OF MIXTURES CONTAINING MORPHOLIN (MO), MONOAMINODIGLYKOL (ADG), AMMONIA AND WATER

PROCEDURE FOR THE PRODUCTION OF NEW ONES BETA SULFO PROPIONSAUREESTERN

PLANT GROWTH-ADJUSTING MEANS

Procedure for the catalytic hydrogenation of bases of the Pyridin and/or Chinolinreihe.

SALTS OF THE PHOSPHOROUS ACID, YOUR COMPOSITIONS AND YOUR USE AS FIREPROOF ACTIVE SUBSTANCES.

PROCEDURE FOR THE PRODUCTION OF NUCLEARSUBSTITUTED DERIVATIVES THE CINNAMOYLANTHRANILSAEURE AND THEIR INTERMEDIATE PRODUCTS.

Method for producing primary amines by means of homogeneously-catalysed alcohol amination

The invention relates to a method for producing primary amines by means of the alcohol amination of alcohols with ammonia, with water being eliminated. The method comprises the steps of: (a) a homogenously-catalysed reaction of a reaction mixture which contains at least one alcohol, ammonia, at least one non-polar solvent, and at least one catalyst containing at least one element selected from groups 8, 9 and 10 of the periodic table in the liquid phase, a product mixture (P) thus being obtained; (b) separating the phases of product mixture (P) which was obtained in step (a), if necessary after a reduction in temperature, a reduction in pressure and/or the addition of at least one polar solvent with a miscibility gap in relation to the non-polar solvent, and thus obtaining at least one polar product phase (A) and at least one non-polar phase (B) containing at least one portion of the catalyst that was introduced, with said non-polar phase (B) being separated off, (c) returning at least ...

PALLADIUM COMPLEXES WITH HETEROCYCLIC LIGANDS

Indane derivatives as mGluR7 modulators

The present invention provides compounds of formula (I) and pharmaceutically acceptable salts thereof, wherein R1, R2, R3, R4 ...

PICOLINIC ACID DERIVATIVES

AMINOBENZOIC ACID DERIVATIVES

ORGANIC COMPOUNDS

.DELTA.-AMINO-.GAMMA.-HYDROXY-.OMEGA.-ARYL-ALKANOIC ACID

Disclosed are .delta.-amino-.gamma.-hydroxy-.omega.-aryl-alkanoic acid amide compounds of formula (I) and the salts thereof, having renin-inhibiting properties. Also disclosed are pharmaceutical compositions comprising these compounds and methods of administering them for the treatment of hypertension, atherosclerosis, unstable coronary syndrome, congestive heart failure, cardiac hypertrophy, cardiac fibrosis, cardiomyopathy postinfarction, unstable coronary syndrome, diastolic dysfunction, chronic kidney disease, hepatic fibrosis, complications resulting from diabetes, such as nephropathy, vasculopathy and neuropathy, diseases of the coronary vessels, restenosis following angioplasty, raised intra-ocular pressure, glaucoma, abnormal vascular growth, hyperaldosteronism, cognitive impairment, alzheimers, dementia, anxiety states and cognitive disorders.

SALTS OF BICYCLO-SUBSTITUTED PYRAZOLON AZO DERIVATIVES, PREPARATION METHOD AND USE THEREOF

The pharmaceutically acceptable salts of bicycle-substituted pyrazolon azo derivatives represented by the general formula (I), their preparation methods, pharmaceutical compositions containing the same and their use as a therapeutic agent, especially as thrombopoietin (TPO) mimetics and their use as agonists of thrombopoietin receptor. The definitions of substituents in the general formula (I) are the same as the description.

B-SULFO-PROPIONIC ACID COMPOUNDS AND PROCESS

ABSTRACT OF THE DISCLOSURE: New .beta.-sulfo-propionic acid compounds and a process for their manufacture by reaction of alcohols, acid amides or amines with .beta.-sulfo-carboxylic acid anhydrides. The compounds are textile assistants, e.g. washing, cleaning or wetting agents, dishwashing detergents, hair shampoos, emulsifiers, flotation agents, plasticizers and starting materials for th manufacture of such agents, as well as for the manufacture of dyes and pesticides.

PHOSPHOROUS ACID SALTS, COMPOSITIONS HOLDING SAME AND THEIR APPLICATION AS FIREPROOFING AGENTS

L'invention concerne des sels d'acide phosphoreux de formules (I) et (II): (I) (II) dans lesquelles: R1 est un hydrogène, un radical hydrocarboné aliphatique substitué ou non par des halogènes ou des groupements amino et ayant de 1 à 6 atomes de carbone, un radical cyclique ou phényle substitué ou non par des halogènes ou des groupements amino; R2 est soit (i) un radical hétérocyclique, ledit radical étant ou non substitué par des halogènes, des groupements amino, des radicaux phényles, cycliques ou alkyles, soit (ii) identique à R1 et R1 et R2 sont pontés par un reste > NH, un hétéroatome ou un reste méthylénique, les deux radicaux R1 dans (II) pouvant être liés; R'2 est un radical aliphatique, cyclique ou hétérocyclique non-substitué ou substitué par des halogènes, des groupements amino, des radicaux phényles, cycliques ou alkyles; Y est un groupement: ou -NH-(CH2)n -NH- avec n compris entre 2 et 6, ou -NH (CH2)2 -NH - (CH2)2 - NH ou une simple ...

METHOD OF PRODUCING MORPHOLINE COMPOUND

NICKEL-BASED DUAL CATALYST SYSTEMS EFFECTIVE IN SUPPRESSING CARBON DIOXIDE FORMATION DURING DIETHYLENE GLYCOL AMINATION

NICKEL-BASED DUAL CATALYST SYSTEMS EFFECTIVE IN SUPPRESSING CARBON DIOXIDE FORMATION DURING DIETHYLENE GLYCOL AMINATION (D#80,931-F) Disclosed is a process for simultaneously producing morpholine and DIGLYCOLAMINE? amine while suppressing C02 formation comprising the steps of: reacting diethylene glycol with ammonia in the presence of added hydrogen over a dual nickel-based catalyst comprising a nickel-copper-chromium oxide mix in combination with nickel-on-alumina, and isolating said morpholine compound and said DIGLYCOLAMINE? amine compound from the reaction products. CLK:pg EX9S/ 80931.app ...

Procédé de préparation d'un dérivé pipéridique substitué en position B et Y.

Procédé de préparation de bases hétérocycliques.

Verfahren zur Herstellung eines cyclischen Amins.

Verfahren zur Herstellung eines cyklischen Amins.

Procédé de préparation d'un nouveau sel de l'acide salicylique.

Procédé de préparation d'un nouveau sel de l'acide salicylique.

Verfahren zur Herstellung ungesättigter Carbonsäuren

Verwendung von Kondensationsprodukten aus Piperazin und Lactonen als Egalisiermittel in der Textilfärberei

Verfahren zur Herstellung einer zu harzartigen Produkten härtbaren Mischung

Verfahren zur Herstellung eines cyclischen Amins.

Verfahren zur Herstellung eines cyclischen Amins.

Verfahren zur Herstellung eines cyclischen Amins.

Verfahren zur Herstellung eines cyclischen Amins.

Verfahren zur Herstellung eines cyclischen Amins.

Verfahren zur Herstellung eines cyclischen Amins.

Verfahren zur Herstellung eines cyclischen Amins.

Procédé de préparation du bis (2,4,5-trichlorophénate) de pipérazine

Kopiermaterial zur Herstellung von Bildern durch Einwirkung von Wärme

Procédé pour préparer des produits antiparasitaires ayant des propriétés tensio-actives

Procédé de préparation des mercapto-succinates de bases azotées

Stabilising org. materials, e.g. polymers against ultraviolet radiatio - with complexes prepd. from acid, amine and nickel salt

Org. Ni complex UV stabilisers (I), their prepn. and the use to stabilise organic materials are claimed, (I) being of formula: (where R1 is tert. 4-14C alkyl; R2 is 1-20C alkyl, 1-12C cycloalkyl, cycloalkylalkyl or phenyl-alkyl in which Ph can be substd. by 1 or 2, 1-6C alkyl or by 1 or 2 halogen atoms, or Ph opt. substd. by 1 or 2, 1-6C alkyl; R3 and R4 are H or 1-8C alkyl; R5 is H, Me, Et, Bu or -CH2-CH2-OH; R6 is 1-18C alkyl opt. substd. by OH, 1-8 C alkoxy or alkylthio or a 5- or 6-membered heterocyclic ring, 1-12C cycloalkyl or cycloalkylalkyl, 7-9C phenyl-alkyl where Ph may be substd. by 1 or 2, 1-4C alkyl and/or OH, Ph opt. substd. by 1 or 2, 1-12C alkyl or alkoxy and/or 1 halogen or Ph opt. substd. by 1 OH and/or 1 or 2, 1-4C alkyl, and total of C atoms in substituents is 1-18C; or R5 and R6 together with common N, opt. with a further heteroatom, form a 5- or 6-membered opt. unsatd. heterocyclic ring; m is 0 or 1; n is 1 or 2; and m + n = 2).

Verfahren zur Herstellung von Piperazin-bis-acetylsalizilat

Verfahren zur Herstellung von Piperazin-di-(N-acetylglycinat)

Procédé de préparation de nouveaux dérivés phénylalcanoylsalicyliques

Procédé de préparation de dérivés de l'acide hydroxycinnamique

Verfahren zur Herstellung von C-substituierten Piperidinen

Verfahren zur Herstellung von Piperazinsalzen

Procédé pour fabriquer un objet creux en matière thermoplastique et dispositif pour la mise en oeuvre de ce procédé

Verfahren zur Herstellung einer Additionsverbindung von Piperazin und 4-Jodthymol

Procédé de préparation de composés hétérocycliques contenant de l'azote nucléaire

Verfahren zur Herstellung von Piperidinderivaten

Verfahren zur Herstellung von Piperidin

PROCEDURE FOR THE PRODUCTION OF NEW OXOINDANYL AND INDANYLPROPIONSAEUREN.

Process for the preparation of beta-sulfo-propionic acid compounds

... beta -Sulpho-propionic acids of the formula Ia, in which the individual symbols have the meanings mentioned in Patent Claim 1, are prepared by reacting suitable amines with beta -sulphocarboxylic anhydrides. The resulting compounds of the formula Ia can be converted into their salts by reacting them with alkali, morpholine or an amine base. The compounds of the formula Ia are textile auxiliaries, dishwashing agents, components of hair shampoos, emulsifiers, floatation auxiliaries, softeners and starting materials for other valuable substances. ...

Processes for preparing novel picolinic acid derivatives.

Herbicide

Process for the preparation of beta-sulpho-propionic acid compounds

... beta -Sulpho-propionic acids of the formula Ia, in which the individual symbols have the meanings mentioned in Patent Claim 1, are prepared by reacting suitable alcohols with beta -sulphocarboxylic anhydrides. …The resulting compounds of the formula Ia can be converted into their salts by reacting them with alkali, morpholine or an amine base. …The compounds of the formula Ia are textile auxiliaries, dishwashing agents, hair shampoos, emulsifiers, floatation auxiliaries, softeners and starting materials for other valuable substances. …… ...

SUBSTITUTED PHENYL ALIPHATIC CARBOXYLIC ACID DERIVATIVES, THEIR PREPARATION AND MEDICAMENTS AND COMPOSITIONS CONTAINING THEM.

КАТАЛИЗАТОР И СПОСОБ ПОЛУЧЕНИЯ АМИНА

Изобретение кается способа получения амина посредством реакции обмена первичного или вторичного спирта, альдегида и/или кетона с водородом и соединением азота, выбранным из группы аммиака, первичных и вторичных аминов, в присутствии содержащего медь, никель и кобальт катализатора на инертном носителе, причем каталитически активная масса катализатора перед восстановлением водородом содержит кислородсодержащие соединения алюминия, меди, никеля и кобальта и 0,2-5,0 мас.% кислородсодержащих соединений олова, рассчитанных как SnO, а также катализаторов, как определено выше.

A METHOD OF PRODUCING THE N-SUBSTITUTED 2,6-DIALKYL MORPHOLINES AND USE OF CATALYST FOR PRODUCING TERTIARY AMINE

METHOD OF PRODUCING N-SUBSTITUTED 2.6 - DIALKILMORFOLINOV

SYNERGISTIC COMPOSITIONS

NEW DERIVATIVES Of ACID AMINOBENZOIQUE, THEIR METHOD OF PREPARATION AND THEIR APPLICATION LIKE SUBSTANCES OF GROWTH OF the PLANTS

NOUVEAUX SELS D'ACIDES CARBOXYLIQUES, PROCEDE POUR LEUR PREPARATION ET COMPOSITIONS PHARMACEUTIQUES LES CONTENANT

LA PRESENTE INVENTION CONCERNE DES COMPOSES CHIMIQUES NOUVEAUX DE FORMULE: (CF DESSIN DANS BOPI) DANS LAQUELLE R, R, R, R ET R REPRESENTENT DES ATOMES D'HYDROGENE OU DES GROUPES HYDROCARBONES ALIPHATIQUES OU CYCLIQUES EVENTUELLEMENT SUBSTITUES DE NATURES VARIEES. CES COMPOSES SONT UTILES NOTAMMENT COMME MEDICAMENT.

ACIDS INDANYLPROPIONIQUES SUBSTITUTE AND THEIR METHOD OF PREPARATION

Y-ALCANES SUBSTITUES OU DES COMPOSES APPARENTES

Produits herbicides contenant des oxydes ou des sulfures de diphényle substitués, dont certains sont nouveaux. Les matières actives qu'ils contiennent répondent à la formule : ...

PROCESS FOR PREPARING MONO-AND DI-ESTERS OF 2,5-DIHYDROXYBENZENE SULPHONIC ACID

Piperazine derivative

COMPOSE Of ACIDS B-SULFOPROPIONIQUE AND PROCESS FOR THEIR PREPARATION

Process for the production of a salt of piperazine and 2,4,5-trichlorophénol

PROCESS FOR PREPARING MORPHOLINE TYPE

NOVEL TRYPTOPHAN DERIVATIVES HAS REINFORCED CENTRAL NERVE ACTIVITY

Salt forms of [R-(R*,R*)]-2-(4-flurorophenyl)-beta, delta-dihydroxy-5-(1-methylethyl)-3-phenyl-4-[phenylamino)carbonyl]-1H-pyrrole-1-heptanoic acid

Novel salt forms of [R—(R*,R*)]-2-(4-fluorophenyl)-β,δ-dihydroxy-5-(1-methylethyl)-3-phenyl-4-[(phenylamino)carbonyl]-1H-pyrrole-1-heptanoic acid characterized by their X-ray powder diffraction pattern and solid-state NMR spectra are described, as well as methods for the preparation and pharmaceutical composition of the same, which are useful as agents for treating hyperlipidemia, hypercholesterolemia, osteoporosis, benign prostatic hyperplasia, and Alzheimer's Disease.

Novel ruthenium complexes and their uses in processes for formation and/or hydrogenation of esters, amides and derivatives thereof

The present invention relates to novel Ruthenium catalysts and related borohydride complexes, and the use of such catalysts, inter alia, for (1) hydrogenation of amides (including polyamides) to alcohols and amines; (2) preparing amides from alcohols with amines (including the preparation of polyamides (e.g., polypeptides) by reacting dialcohols and diamines and/or by polymerization of amino alcohols); (3) hydrogenation of esters to alcohols (including hydrogenation of cyclic esters (lactones) or cyclic di-esters (di-lactones) or polyesters); (4) hydrogenation of organic carbonates (including polycarbonates) to alcohols and hydrogenation of carbamates (including polycarbamates) or urea derivatives to alcohols and amines; (5) dehydrogenative coupling of alcohols to esters; (6) hydrogenation of secondary alcohols to ketones; (7) amidation of esters (i.e., synthesis of amides from esters and amines); (8) acylation of alcohols using esters; (9) coupling of alcohols with water to form carboxylic acids; and (10) dehydrogenation of beta-amino alcohols to form pyrazines. The present invention further relates to the novel uses of certain pyridine Ruthenium catalysts.

Salt forms of [R-(R*,R*)]-2-(4-fluorophenyl)-beta, delta-dihydroxy-5-(1-methylethyl)-3-phenyl-4-[phenylamino)carbonyl]-1H-pyrrole-1-heptanoic acid

Novel salt forms of [R—(R*,R*)]-2-(4-fluorophenyl)-β,δ-dihydroxy-5-(1-methylethyl)-3-phenyl-4-[(phenylamino)carbonyl]-1H-pyrrole-1-heptanoic acid characterized by their X-ray powder diffraction pattern and solid-state NMR spectra are described, as well as methods for the preparation and pharmaceutical composition of the same, which are useful as agents for treating hyperlipidemia, hypercholesterolemia, osteoporosis, benign prostatic hyperplasia, and Alzheimer's Disease.

Diamine and meglumine salt forms of fatty acids

Provided herein are diamine salts of eicosapentaenoic acid and docosahexaenoic acid, processes for the preparation of such compounds, pharmaceutical compositions comprising such compounds, and the uses of such compounds as agents for treating dyslipidemia, cardiovascular diseases such as cardiac arrhythmia, cardiac ischemia, myocardial infarction, cardiomyopathy, and stroke and obesity.

Process for Preparing Pyrrolidine

Process for preparing pyrrolidine of the formula I 128-. (canceled)30. The process according to claim 29 , wherein the catalytically active mass of the catalyst claim 29 , prior to its reduction with hydrogen claim 29 , comprises in the range from 0.4 to 4.0% by weight of oxygen-containing compounds of tin claim 29 , calculated as SnO.31. The process according to claim 29 , wherein the catalytically active mass of the catalyst claim 29 , prior to its reduction with hydrogen claim 29 , comprises in the range from 0.6 to 3.0% by weight of oxygen-containing compounds of tin claim 29 , calculated as SnO.32. The process according to claim 29 , wherein the catalytically active mass of the catalyst claim 29 , prior to its reduction with hydrogen claim 29 , comprises in the range from 5.0 to 35% by weight of oxygen-containing compounds of cobalt claim 29 , calculated as CoO.33. The process according to claim 29 , wherein the catalytically active mass of the catalyst claim 29 , prior to its reduction with hydrogen claim 29 , comprises in the range from 10 to 30% by weight of oxygen-containing compounds of cobalt claim 29 , calculated as CoO.34. The process according to claim 29 , wherein the catalytically active mass of the catalyst claim 29 , prior to its reduction with hydrogen claim 29 , comprises in the range from{'sub': 2', '3, '15 to 80% by weight of oxygen-containing compounds of aluminum, calculated as AlO,'}1.0 to 20% by weight of oxygen-containing compounds of copper, calculated as CuO, and5.0 to 35% by weight of oxygen-containing compounds of nickel, calculated as NiO.35. The process according to claim 29 , wherein the catalytically active mass of the catalyst claim 29 , prior to its reduction with hydrogen claim 29 , comprises in the range from{'sub': 2', '3, '30 to 70% by weight of oxygen-containing compounds of aluminum, calculated as AlO,'}2.0 to 18% by weight of oxygen-containing compounds of copper, calculated as CuO, and10 to 30% by weight of oxygen- ...

Immobilized Ruthenium-Triphos Catalysts for Selective Hydrogenolysis of Amides

A compound represented by the structure of formula (I): 5. The compound of claim 4 , wherein L comprises trimethylenemethane.7. The method of claim 6 , wherein the Ru-containing compound comprises [Ru(COD)(methylallyl)].8. A catalyst composition comprising:(a) an oxidic support; and{'claim-ref': {'@idref': 'CLM-00004', 'claim 4'}, '(b) the compound of immobilized on the support.'}9. The catalyst composition of claim 8 , wherein the oxidic support comprises silica claim 8 , magnesia claim 8 , titania claim 8 , or alumina.10. The catalyst composition of claim 8 , wherein the oxidic support comprises silica.11. The catalyst composition of claim 8 , wherein L comprises trimethylenemethane.13. The process of claim 12 , wherein the oxidic support comprises silica claim 12 , magnesia claim 12 , titania claim 12 , and alumina.14. The process of claim 12 , wherein the oxidic support comprises silica.15. The process of claim 12 , wherein L comprises trimethylenemethane.16. The process of claim 13 , wherein L comprises trimethylenemethane.17. The process of claim 14 , wherein L comprises trimethylenemethane.18. The process of claim 12 , wherein the amide comprises a lactam.19. The process of claim 13 , wherein the amide comprises a lactam.20. The process of claim 17 , wherein the amide comprises a lactam. This is application claims the benefit of Provisional Application No. 62/691,936 filed on Jun. 29, 2018 under 35 U.S.C. § 119(e)(1); the entire content of the provisional application is hereby incorporated by reference.The invention generally relates to the field of organic chemistry. It particularly relates to silyl ether triphos compounds, organometallic complexes containing the silyl ether triphos compounds, catalysts containing the organometallic complexes immobilized on oxidic supports, methods of making, and/or methods of using the compounds, complexes, and catalysts.The hydrogenolysis of amides to amines under mild reaction conditions represents a challenging chemical ...

Calpain modulators and therapeutic uses thereof

Small molecule calpain modulator compounds, including their pharmaceutically acceptable salts, can be included in pharmaceutical compositions. The compounds can be useful in inhibiting calpain, or competitive binding with calpastatin, by contacting them with CAPN1, CAPN2, and/or CAPN9 enzymes residing inside a subject. The compounds and composition can also be administered to a subject in order to treat a fibrotic disease or a secondary disease state or condition of a fibrotic disease.

Amine salts of prostaglandin analogs

The present application relates to amine salts of prostaglandin analogs and their uses for the preparation of substantially pure prostaglandin analogs. Specific embodiments relate to amine salts of tafluprost and their uses for the preparation of substantially pure tafluprost.

Hydrogenation reaction catalyst used to hydrogenate amide compound and method for producing amine compound using same

A catalyst, which can be used even under mild conditions and also has durability so as to enable repeated use while maintaining high activity, and with which a reduction reaction for converting an amide compound into an amine compound can be carried out, is provided by means of an amide compound hydrogenation reaction catalyst characterized in that platinum and vanadium are supported on a carrier and a method for producing an amine compound using the same.

Organo-1-oxa-4-azonium cyclohexane compounds

Novel 1-oxa-4-azonium cyclohexane salts are described. These compounds can be used as structure directing agents, and they overcome many of the typical problems associated with OSDA synthesis and subsequent zeolite synthesis. Methods for synthesis of the 1-oxa-4-azonium cyclohexane salts from a variety of starting materials are also described. A substituted hydrocarbon is added to water to form a mixture, and a 1-oxa-4-azacyclohexane derivative is then added. The reaction mixture stirred until a solution containing the 1-oxa-4-azonium cyclohexane salt is obtained.

SALTS OF BICYCLO-SUBSTITUTED PYRAZOLON AZO DERIVATIVES, PREPARATION METHOD AND USE THEREOF

The pharmaceutically acceptable salts of bicycle-substituted pyrazolon azo derivatives represented by the general formula (I), their preparation methods, pharmaceutical compositions containing the same and their use as a therapeutic agent, especially as thrombopoietin (TPO) mimetics and their use as agonists of thrombopoietin receptor. The definitions of substituents in the general formula (I) are the same as the description. 1. (canceled)3. The method according to claim 2 , wherein the pharmaceutical salt is co-administered with a drug selected from the group consisting of a colony stimulating factor claim 2 , a cytokine claim 2 , a chemokine claim 2 , an interleukin or cytokine receptor agonist or antagonist claim 2 , a soluble receptor claim 2 , a receptor agonist or antagonist antibody claim 2 , or one or more peptides or small molecule compounds that have the same mechanism as the drug.4. The method according to claim 2 , wherein the pharmaceutical salt is in the form of an oral dosage form.5. The method according to claim 2 , wherein the dosage form is a parenteral dosage form.6. The method of claim 2 , wherein the pharmaceutically acceptable salt of the compound having formula (I) is a base addition salt.7. The method of claim 2 , wherein the pharmaceutically acceptable salt of the compound having formula (I) is selected from the group consisting of sodium salt claim 2 , lithium salt claim 2 , potassium salt claim 2 , calcium salt claim 2 , magnesium salt claim 2 , arginine salt claim 2 , lysine salt claim 2 , methanamine salt claim 2 , dimethylamine salt claim 2 , trimethylamine salt claim 2 , ethylamine salt claim 2 , diethylamine salt claim 2 , triethylamine salt claim 2 , ethanolamine salt claim 2 , piperazine salt claim 2 , dibenzyl ethylenediamin salt claim 2 , meglumine salt claim 2 , tromethamine salt claim 2 , tetramethyl quaternary ammonium salt claim 2 , tetraethyl quaternary ammonium salt claim 2 , choline salt claim 2 , and combinations thereof.8 ...

SYNERGISTIC COMPOSITIONS

The present invention describes a synergistic composition comprising of one or more statins, or one or more dipeptidyl peptidase IV (DPP IV) inhibitor or one or more biguanide antihyperglycaemic agent and a PPAR agonist of formula (Ia) 2. The synergistic composition as claimed in claim 1 , wherein the one or more DPP IV inhibitors are selected from Sitagliptin claim 1 , Vildagliptin claim 1 , Saxagliptin claim 1 , Alogliptin and Linagliptin.3. The synergistic composition as claimed in claim 1 , wherein the one or more statins are selected from Lovastatin claim 1 , Pravastatin claim 1 , Fluvastatin claim 1 , Simvastatin claim 1 , Atorvastatin claim 1 , Rosuvastatin and Pitavastatin.4. The synergistic composition as claimed in claim 1 , wherein the one or more biguanide antihyperglycaemic agents are selected from Metformin claim 1 , Buformin or Phenformin.5. The synergistic composition as claimed in claim 1 , wherein the one or more thiazolidinediones are selected from Pioglitazone and Rosiglitazone.6. The synergistic composition as claimed in claim 1 , wherein the one or more sulphonylureas are selected from glibenclamide claim 1 , glipizide claim 1 , gliclazide claim 1 , glimepiride claim 1 , tolazamide claim 1 , tolbutamide claim 1 , acetohexamide claim 1 , carbutamide claim 1 , chlorpropamide claim 1 , glibomuride claim 1 , gliquidone claim 1 , glisentide claim 1 , glisolamide claim 1 , glisoxepide claim 1 , glyclopyamide claim 1 , glycylamide and glipentide.7. The synergistic composition as claimed in claim 1 , wherein the one or more SGLT-2 inhibitors are selected from Dapagliflozin claim 1 , Canagliflozin claim 1 , Empagliflozin claim 1 , Ertugliflozin and Ipragliflozin.8. The synergistic composition as claimed in claim 1 , wherein the one or more GLP-1 agonists are selected from Exenatide claim 1 , Liraglutide and Dulaglutide.9. (canceled)10. A method for the treatment of dyslipidemia claim 1 , hypertriglyceridemia or diabetes mellitus which comprises ...

SELECTIVE HYDROGENATION CATALYST AND SELECTIVE HYDROGENATION METHOD USING THE SAME

The present invention relates to a Ru—Pd bimetallic catalyst for use in hydrogenation of a compound, and more particularly to a catalyst prepared by loading both ruthenium and palladium on a g-CNsupport and to a selective hydrogenation process of a pyridine group in a reaction system containing both a pyridine group and a benzene group using the catalyst. 2. The selective hydrogenation catalyst of claim 1 , wherein a weight ratio (b/a) of the ruthenium (b) relative to the palladium (a) ranges from 0.25 to 10.3. A method of preparing a selective hydrogenation catalyst claim 1 , comprising:{'sub': 3', '4, 'a) preparing a support solution by dispersing a g-CNsupport in distilled water;'}b) preparing a catalyst precursor solution by adding the support solution with a ruthenium precursor and a palladium precursor such that a sum of weights of ruthenium and palladium as active components is 0.1 to 15 wt % based on a total weight of the catalyst including the support; andc) drying the catalyst precursor solution and then performing heat treatment in a hydrogen atmosphere.4. The method of claim 3 , wherein claim 3 , in step b) claim 3 , a weight ratio (b/a) of the ruthenium (b) relative to the palladium (a) ranges from 0.25 to 10.5. The method of claim 3 , wherein claim 3 , in step c) claim 3 , the heat treatment in the hydrogen atmosphere is performed at a temperature ranging from 250 to 500° C.7. The selective hydrogenation method of claim 6 , wherein the benzene compound is at least one selected from among benzene claim 6 , toluene claim 6 , xylene claim 6 , cyclohexyltoluene claim 6 , diphenylmethane claim 6 , benzyl alcohol claim 6 , phenylethyl alcohol claim 6 , methyl phenyl ether claim 6 , and ethyl phenyl ether.8. The selective hydrogenation method of claim 6 , wherein the pyridine compound is at least one selected from among pyridine claim 6 , methylpyridine claim 6 , ethylpyridine claim 6 , cyclohexyl methylpyridine claim 6 , benzylpyridine claim 6 , ...

RHENIUM RECOVERY FROM USED REDUCTIVE AMINATION CATALYSTS

The present invention provides techniques that selectively recover Re from reductive amination catalysts. In particular, the present invention allows Re to be recovered selectively relative to Ni, Co, and/or Cu, and particularly Ni, that are often present on reductive amination catalysts. The present invention uses a combination of oxidation and extraction techniques to selectively recover Re relative to Ni, Co, and/or Cu. Advantageously, the recovery is selective even when using aqueous solutions for extraction. 1. A method for recovering rhenium from a reductive amination catalyst , comprising the steps of:a) providing a heterogeneous catalyst that has been used in a reducing atmosphere to carry out a reductive amination, wherein the catalyst comprises a substrate and at least one species comprising rhenium and at least one species comprising nickel supported on the substrate, wherein the at least one species comprising rhenium has a first solubility in a liquid carrier, and wherein the substrate comprises at least 15 weight percent alumina based on the total weight of the substrate;b) causing the catalyst to contact the liquid carrier in the presence of heat and at least one oxidizing agent under conditions effective to convert at least a portion of the Re-containing species into a Re-containing product that has a second solubility in the liquid carrier, wherein the second solubility is greater than the first solubility; andc) extracting the Re-containing product into the liquid carrier.2. The method of claim 1 , wherein the substrate comprises a guest/host structure and the heterogenous catalyst is supported at least upon the guest particles.3. The method of claim 1 , wherein step (a) comprises calcining and reducing the substrate.4. The method of claim 1 , wherein the substrate comprises alumina and silica.5. The method of claim 1 , wherein the heterogeneous catalyst further comprises at least one of a Co-containing species and a Cu-containing species.6. The ...

Catalysts and processes for the hydrogenation of amides

There is provided a process for the reduction of one or more amide moieties in a compound comprising contacting the compound with hydrogen gas and a transition metal catalyst in the presence or absence of a base under conditions for the reduction an amide bond. The presently described processes can be performed at low catalyst loading using relatively mild temperature and pressures, and optionally, in the presence or absence of a base or high catalyst loadings using low temperatures and pressures and high loadings of base to effect dynamic kinetic resolution of achiral amides.

NOVEL RUTHENIUM COMPLEXES AND THEIR USES IN PROCESSES FOR FORMATION AND/OR HYDROGENATION OF ESTERS, AMIDES AND DERIVATIVES THEREOF

The present invention relates to novel Ruthenium complexes and related borohydride complexes, and their use for (1) hydrogenation of amides (including polyamides) to alcohols and amines; (2) preparing amides from alcohols with amines (including preparing polyamides (e.g., polypeptides) by reacting dialcohols and diamines or by polymerization of amino alcohols); (3) hydrogenation of esters to alcohols (including hydrogenation of cyclic esters (lactones), cyclic di-esters (di-lactones) or polyesters); (4) hydrogenation of organic carbonates (including polycarbonates) to alcohols and of carbamates (including polycarbamates) or urea derivatives to alcohols and amines; (5) dehydrogenative coupling of alcohols to esters; (6) hydrogenation of secondary alcohols to ketones; (7) amidation of esters (synthesis of amides from esters and amines); (8) acylation of alcohols using esters; (9) coupling of alcohols with water to form carboxylic acids; and (10) dehydrogenation of beta-amino alcohols to form pyrazines. The present invention further relates to novel uses of certain pyridine Ruthenium complexes. 4. The process according to claim 1 , wherein Xand/or Xare absent claim 1 , and the pyridyl or bipyridy moiety is unsubstituted.5. The process according to claim 1 , wherein Lis phosphine (PRR).13. The process according to claim 10 , wherein Xand/or Xare absent claim 10 , and the pyridyl or bipyridy moiety is unsubstituted.14. The process according to claim 10 , wherein Lis phosphine (PRR).16. The process of claim 10 , for preparing an amide from amine and an alcohol claim 10 , wherein the process is for preparing a polypeptide or a cyclic dipeptide claim 10 , and wherein the primary or secondary amine and the primary alcohol are a beta-aminoalcohol. This application is a Divisional Application from U.S. application Ser. No. 14/702,641 filed May 1, 2015, which is a Divisional Application from U.S. application Ser. No. 13/880,328 filed Jun. 11, 2013 now U.S. Pat. No. 9,045,381, ...

COMPOSITIONS AND METHODS FOR THE TREATMENT OF MULTIPLE SCLEROSIS

The invention relates to the compounds of formula I and formula II or its pharmaceutical acceptable polymorphs, solvates, enantiomers, stereoisomers and hydrates thereof. The pharmaceutical compositions comprising an effective amount of salts of formula I or formula II; and methods for treating or preventing multiple sclerosis may be formulated for oral, buccal, rectal, topical, transdermal, transmucosal, intravenous, parenteral administration, syrup, or injection. Such compositions may be used to treatment of neurodegenerative diseases and psoriasis. 3. A Pharmaceutical composition comprising a compound of and a pharmaceutically acceptable carrier.4. A Pharmaceutical composition comprising a compound of and a pharmaceutically acceptable carrier.5. The pharmaceutical composition of claim 3 , which is formulated to treat the underlying etiology with an effective amount administering the patient in need by oral administration claim 3 , delayed release or sustained release claim 3 , transmucosal claim 3 , syrup claim 3 , topical claim 3 , parenteral administration claim 3 , injection claim 3 , subdermal claim 3 , oral solution claim 3 , rectal administration claim 3 , buccal administration or transdermal administration.6. The pharmaceutical composition of claim 4 , which is formulated to treat the underlying etiology with an effective amount administering the patient in need by oral administration claim 4 , delayed release or sustained release claim 4 , transmucosal claim 4 , syrup claim 4 , topical claim 4 , parenteral administration claim 4 , injection claim 4 , subdermal claim 4 , oral solution claim 4 , rectal administration claim 4 , buccal administration or transdermal administration.7. Compounds and compositions of are formulated for the treatment of neurodegenerative diseases claim 5 , multiple sclerosis claim 5 , psoriasis and inflammatory diseases.8. Compounds and compositions of are formulated for the treatment of neurodegenerative diseases claim 6 , ...

Use of type of compounds as energy-containing material

The present application belongs to the field of energetic compounds, and particularly relates to the use of a perovskite-type compound ABX3 as an energetic material. As a finding of the present application, the structural characteristics of the perovskite type enables the type of compound to be highly stable, thus overcoming the unsafety of an explosive having poor stability in the prior art. Meanwhile, the structural characteristics of the compound, such as rich energetic ligands, as well as the alternately arranged oxidizing energetic anions and reducing organic cations in the space, endow the compound with excellent performance on instantaneously releasing energy at detonation. The resulting three-dimensional structure allows the compound to not only have an energetic material effect but also overcome shortcomings of some existing energetic materials.

PHARMACEUTICALLY ACCEPTABLE SALTS OF FATTY ACIDS

The present disclosure provides pharmaceutically acceptable stable salt forms of 15-lipoxygenase products, such as 15-HETrE lysine salt, compositions comprising same and methods of making and using same. 1. A salt of a 15-lipoxygenase product.2. The salt of claim 1 , wherein the salt is a pharmaceutically acceptable salt.3. The salt of claim 1 , wherein the salt comprises a lysine salt of the 15-lipoxygenase product.4. The salt of claim 1 , wherein the salt comprises a sodium salt of the 15-lipoxygenase product.5. The salt of claim 1 , wherein the salt comprises an ornithine salt of the 15-lipoxygenase product.6. The salt of claim 1 , wherein the salt comprises a piperazine salt of the 15-lipoxygenase product.7. The salt of claim 1 , wherein the salt comprises a meglumine salt of the 15-lipoxygenase product.8. The salt of further comprising the 15-lipoxygenase product in free acid form.9. The salt of claim 1 , wherein the salt is selected from the group consisting of: sodium claim 1 , lysine claim 1 , ornithine claim 1 , piperazine claim 1 , meglumine claim 1 , and combinations thereof.10. The salt of claim 1 , wherein the 15-lipoxygenase product is selected from the group consisting of: 13-HODE claim 1 , 15-HETrE claim 1 , 15-OHEPA claim 1 , 15-HETE claim 1 , and combinations thereof.11. 15-Hydroxy-5 claim 1 , 8 claim 1 ,11 claim 1 ,13-eicosatetraenoic acid lysine salt.12. A pharmaceutical composition comprising a salt form of a 15-lipoxygenase product.13. The pharmaceutical composition of further comprising an excipient.14. The pharmaceutical composition of claim 12 , wherein after storage for at least about 4 weeks claim 12 , the pharmaceutical composition comprises at least about 98% claim 12 , at least about 99% claim 12 , or about 100% of an initial amount of the salt form of the 15-lipoxygenase product.15. The pharmaceutical composition of claim 12 , wherein after storage for at least about 10 weeks or at least 24 weeks claim 12 , the pharmaceutical ...

Pharmaceutically Acceptable Salts of Fatty Acids

The present disclosure provides pharmaceutically acceptable stable salt forms of 15-lipoxygenase products, such as 15-HETrE lysine salt, compositions comprising same and methods of making and using same. 1. A salt of a 15-lipoxygenase product.2. The salt of claim 1 , wherein the salt is a pharmaceutically acceptable salt.3. The salt of claim 1 , wherein the salt comprises a lysine salt of the 15-lipoxygenase product.4. The salt of claim 1 , wherein the salt comprises a sodium salt of the 15-lipoxygenase product.5. The salt of claim 1 , wherein the salt comprises an ornithine salt of the 15-lipoxygenase product.6. The salt of claim 1 , wherein the salt comprises a piperazine salt of the 15-lipoxygenase product.7. The salt of claim 1 , wherein the salt comprises a meglumine salt of the 15-lipoxygenase product.8. The salt of further comprising the 15-lipoxygenase product in free acid form.9. The salt of claim 1 , wherein the salt is selected from the group consisting of: sodium claim 1 , lysine claim 1 , ornithine claim 1 , piperazine claim 1 , meglumine claim 1 , and combinations thereof.10. The salt of claim 1 , wherein the 15-lipoxygenase product is selected from the group consisting of: 13-HODE claim 1 , 15-HETrE claim 1 , 15-OHEPA claim 1 , 15-HETE claim 1 , and combinations thereof.11. 15-Hydroxy-5 claim 1 ,8 claim 1 ,11 claim 1 ,13-eicosatetraenoic acid lysine salt.12. A pharmaceutical composition comprising a salt form of a 15-lipoxygenase product.13. The pharmaceutical composition of further comprising an excipient.14. The pharmaceutical composition of claim 12 , wherein after storage for at least about 4 weeks claim 12 , the pharmaceutical composition comprises at least about 98% claim 12 , at least about 99% claim 12 , or about 100% of an initial amount of the salt form of the 15-lipoxygenase product.15. The pharmaceutical composition of claim 12 , wherein after storage for at least about 10 weeks or at least 24 weeks claim 12 , the pharmaceutical ...

ORGANO-1-OXA-4-AZONIUM CYCLOHEXANE COMPOUNDS

Novel 1-oxa-4-azonium cyclohexane salts are described. These compounds can be used as structure directing agents, and they overcome many of the typical problems associated with OSDA synthesis and subsequent zeolite synthesis. Methods for synthesis of the 1-oxa-4-azonium cyclohexane salts from a variety of starting materials are also described. 2. The morpholinium compound of having the Formula 3 claim 1 , wherein X is hydroxide.3. The morpholinium compound of having the Formula 3 claim 1 , wherein R-Rare H.4. The morpholinium compound of having the Formula 1 wherein Rand Rform the cyclic alkyl group claim 3 , or having the Formula 4 wherein at least one of Rand Ris the alkyl group having the formula CH.5. The morpholinium compound of having the Formula 3 claim 1 , wherein at least one of R-Ris the alkyl group.6. The morpholinium compound of having the Formula 1 wherein Rand Rform the cyclic alkyl group claim 5 , or having the Formula 4 wherein at least one of Rand Ris the alkyl group having the formula CH.7. The morpholinium compound of having the Formula 1 wherein m is 5 claim 1 , R-Rare H claim 1 , and X is a halide.8. The morpholinium compound of having the Formula 2 wherein x is 1 claim 1 , and y is m.9. The morpholinium compound of having the Formula 3 wherein when Ris the alkyl group claim 1 , X is hydroxide.10. The morpholinium compound of having the Formula 2 wherein Ris the alkyl group and n is 1 claim 1 , m is 4 claim 1 , x is 1 claim 1 , and y is 4.11. The morpholinium compound of having the Formula 3 claim 1 , wherein at least two of R-Rare the alkyl group claim 1 , and wherein the at least two of R-Rare Rand R claim 1 , or Rand R claim 1 , or Rand R claim 1 , or Rand R.12. The morpholinium compound of having the Formula 4 wherein at least two of R-Rare the alkyl group claim 1 , and wherein at least one of Rand Ris the alkyl group having the formula CH claim 1 , or the Formula 1 wherein Rand Rform the cyclic alkyl group.13. The morpholinium compound of ...

Salt forms of [R-(R*,R*)]-2-(4-fluorophenyl)-beta,delta-dihydroxy-5-(1-methylethyl)-3-phenyl-4-[(phenylamino)carbonyl]-1H-pyrrole-1-heptanoic acid

Novel salt forms of [R—(R*,R*)]-2-(4-fluorophenyl)-β,δ-dihydroxy-5-(1-methylethyl)-3-phenyl-4-[(phenylamino)carbonyl]-1H-pyrrole-1-heptanoic acid characterized by their X-ray powder diffraction pattern and solid-state NMR spectra are described, as well as methods for the preparation and pharmaceutical composition of the same, which are useful as agents for treating hyperlipidemia, hypercholesterolemia, osteoporosis, benign prostatic hyperplasia, and Alzheimer's Disease. 1. An atorvastatin ammonium or hydrate thereof having an x-ray powder diffraction pattern containing the following 2θ peaks measured using CuKradiation: 7.8 , 8.8 , 9.3 , 9.9 , 10.6 , 12.4 , and 19.5.2. (canceled)3. (canceled)4. (canceled)5. (canceled)6. (canceled)7. (canceled)8. (canceled)9. An atorvastatin erbumine or hydrate thereof having an x-ray powder diffraction pattern containing the following 2θ peaks measured using CuKradiation: 5.4 , 7.3 , 9.5 , 17.8 , 19.2 , 20.0 , 22.2 , and 24.2 , or a solid state F nuclear magnetic resonance having the following chemical shifts expressed in parts per million: −110.4.10. An atorvastatin L-lysine or hydrate thereof having an x-ray powder diffraction pattern containing the following 2θ peaks measured using CuKradiation: 6.7 , 9.8 , 17.1 , and 24.0.11. (canceled)12. (canceled)13. An atorvastatin piperazine or hydrate thereof having an x-ray powder diffraction pattern containing the following 2θ peaks measured using CuKradiation: 7.8 , 9.3 , 11.8 , 16.1 , and 19.7.14. An atorvastatin sodium or hydrate thereof having an x-ray powder diffraction pattern containing the following 2θ peaks measured using CuKradiation: 3.4 , 4.9 , 7.6 , 8.0 , 9.9 , 18.9 , and 19.7.15. An atorvastatin 2-amino-2-methylpropan-1-ol or hydrate thereof having an x-ray powder diffraction pattern containing the following 2θ peaks measured using CuKradiation: 4.2 , 8.3 , 16.0 , 17.5 , 18.3 , 19.4 , and 19.7 , or a solid state F nuclear magnetic resonance having the following chemical ...

SALT FORMS OF [R-(R*,R*)]-2-(4-FLUOROPHENYL)-BETA,DELTA-DIHYDROXY-5-(1-METHYLETHYL)-3-PHENYL-4-[(PHENYLAMINO)CARBONYL]-1H-PYRROLE-1-HEPTANOIC ACID

Novel salt forms of [R—(R*,R*)]-2-(4-fluorophenyl)-β,δ-dihydroxy-5-(1-methylethyl)-3-phenyl-4-[(phenylamino)carbonyl]-1H-pyrrole-1-heptanoic acid characterized by their X-ray powder diffraction pattern and solid-state NMR spectra are described, as well as methods for the preparation and pharmaceutical composition of the same, which are useful as agents for treating hyperlipidemia, hypercholesterolemia, osteoporosis, benign prostatic hyperplasia, and Alzheimer's Disease. 1. An atorvastatin ammonium or hydrate thereof having an x-ray powder diffraction pattern containing the following 2θ peaks measured using CuKradiation: 7.8 , 8.8 , 9.3 , 9.9 , 10.6 , 12.4 , and 19.5.2. (canceled)3. (canceled)4. (canceled)5. (canceled)6. (canceled)7. (canceled)8. (canceled)9. An atorvastatin erbumine or hydrate thereof having an x-ray powder diffraction pattern containing the following 2θ peaks measured using CuKradiation: 5.4 , 7.3 , 9.5 , 17.8 , 19.2 , 20.0 , 22.2 , and 24.2 , or a solid state F nuclear magnetic resonance having the following chemical shifts expressed in parts per million: −110.4.10. An atorvastatin L-lysine or hydrate thereof having an x-ray powder diffraction pattern containing the following 2θ peaks measured using CuKradiation: 6.7 , 9.8 , 17.1 , and 24.0.11. (canceled)12. (canceled)13. An atorvastatin piperazine or hydrate thereof having an x-ray powder diffraction pattern containing the following 2θ peaks measured using CuK radiation: 7.8 , 9.3 , 11.8 , 16.1 , and 19.7.14. An atorvastatin sodium or hydrate thereof having an x-ray powder diffraction pattern containing the following 2θ peaks measured using CuK radiation: 3.4 , 4.9 , 7.6 , 8.0 , 9.9 , 18.9 , and 19.7.15. (canceled) The present invention relates to novel salt forms of atorvastatin which is known by the chemical name [R—(R*,R*)]-2-(4-fluorophenyl)-β,δ-dihydroxy-5-(1-methylethyl)-3-phenyl-4-[(phenylamino)carbonyl]-1H-pyrrole-1-heptanoic acid, useful as pharmaceutical agents, to methods for their ...

PHARMACEUTICALLY ACCEPTABLE SALTS OF FATTY ACIDS

The present disclosure provides pharmaceutically acceptable stable salt forms of 15-lipoxygenase products, such as 15-HETrE lysine salt, compositions comprising same and methods of making and using same. 1. A salt of a 15-lipoxygenase product.2. The salt of claim 1 , wherein the salt is a pharmaceutically acceptable salt.3. The salt of claim 1 , wherein the salt comprises a lysine salt of the 15-lipoxygenase product.4. The salt of claim 1 , wherein the salt comprises a sodium salt of the 15-lipoxygenase product.5. The salt of claim 1 , wherein the salt comprises an ornithine salt of the 15-lipoxygenase product.6. The salt of claim 1 , wherein the salt comprises a piperazine salt of the 15-lipoxygenase product.7. The salt of claim 1 , wherein the salt comprises a meglumine salt of the 15-lipoxygenase product.8. The salt of further comprising the 15-lipoxygenase product in free acid form.9. The salt of claim 1 , wherein the salt is selected from the group consisting of: sodium claim 1 , lysine claim 1 , ornithine claim 1 , piperazine claim 1 , meglumine claim 1 , and combinations thereof.10. The salt of claim 1 , wherein the 15-lipoxygenase product is selected from the group consisting of: 13-HODE claim 1 , 15-HETrE claim 1 , 15-OHEPA claim 1 , 15-HETE claim 1 , and combinations thereof.11. 15-Hydroxy-5 claim 1 ,8 claim 1 ,11 claim 1 ,13-eicosatetraenoic acid lysine salt.12. A pharmaceutical composition comprising a salt form of a 15-lipoxygenase product.13. The pharmaceutical composition of further comprising an excipient.14. The pharmaceutical composition of claim 12 , wherein after storage for at least about 4 weeks claim 12 , the pharmaceutical composition comprises at least about 98% claim 12 , at least about 99% claim 12 , or about 100% of an initial amount of the salt form of the 15-lipoxygenase product.15. The pharmaceutical composition of claim 12 , wherein after storage for at least about 10 weeks or at least 24 weeks claim 12 , the pharmaceutical ...

METHOD FOR THE MANUFACTURING OF 2-(3-(ALKYL AND ALKENYL)MORPHOLINO)-ETHAN-1-OLS

The present invention relates to a method for the manufacture of 2-(3-(alkyl or alkenyl)morpholino)-ethan-1-ols by reduction of 8a-(alkyl and alkenyl)hexahydrooxazolo[2,3-c][1,4]oxazines encompassing a process for producing 2-(3-(4-propylheptyllmorpholino)ethan-1-ol with the INN name delmopinol. The invention also relates to 1-chloro-4-propylhept-3-ene, 1-iodo-4-propylhept-3-ene, 8a-(4-5 propylheptyl)hexahydrooxazolo[2,3-c] [1,4]oxazine, 8a-(4-propylhept-3-en-1-yl)hexahydrooxazo-lo[2,3-c][1,4]oxazine and 2-(3-(4-propylhept-3-en-1-yl)morpholino)ethan-1-ol which are intermediates in the delmopinol process. 115.-. (canceled) The present invention relates to a method for the manufacture of 2-(3-(alkyl or alkenyl)morpholino)-ethan-1-ols by reduction of 8a-(alkyl or alkenyl)hexahydrooxazolo[2,3-c][1,4]oxazines encompassing a process for producing 2-(3-(4-propylheptyl)morpholino)ethan-1-ol with the INN name delmopinol. The invention also relates to intermediates including 1-chloro-4-propylhept-3-ene, 1-iodo-4-propylhept-3-ene, 8a-(4-propylheptyl)hexahydrooxazolo[2,3-c][1,4]oxazine, 8a-(4-propylhept-3-en-1-yl)hexahydrooxazolo[2,3-c][1,4]oxazine and 2-(3-(4-propylhept-3-en-1-yl)morpholino)ethan-1-ol which are intermediates in the delmopinol process.The compound 2-(3-(4-propylheptyl)morpholino)ethan-1-ol (CAS 79874-76-3) having the INN name delmopinol was disclosed for the first time by Ferrosan in EP0038785 and has the molecular structure depicted below.Delmopinol is used in the treatment of gingivitis, prevention of plaque formation and for oral hygiene in general. It is an active component in mouth wash liquids and toothpaste for use in humans and is also used in the maintenance of oral health in animals as described in WO 2007/099302. Ferrosan in EP0038785 disclosed methods for the synthesis of 2-(3-alkylmorpholino)-ethan-1-ol derivatives and the use of their pharmaceutically acceptable salts for the treatment of the oral cavity. The described methods have several ...

SUBSTITUTED BENZYLAMINE COMPOUNDS, THEIR USE IN MEDICINE, AND IN PARTICULAR THE TREATMENT OF HEPATITIS C VIRUS (HCV) INFECTION

The invention provides compounds of the formula (6): 2. A compound according to claim 1 , or a salt claim 1 , N-oxide or tautomer thereof claim 1 , wherein A is CH and E is CH.3. A compound according to claim 1 , or a salt claim 1 , N-oxide or tautomer thereof claim 1 , wherein Ris hydrogen.4. A compound according to claim 1 , or a salt claim 1 , N-oxide or tautomer thereof claim 1 , wherein Ris selected from:{'sub': 1-8', '1-8, 'sup': '6', 'an acyclic Chydrocarbon group optionally substituted with one substituent R, wherein one carbon atom of the acyclic Chydrocarbon group may optionally be replaced by a heteroatom O; and'}{'sup': '7a', 'a monocyclic carbocyclic or heterocyclic group of 3, 4, 5 or 6 ring members, of which 0, 1 or 2 are heteroatom ring members selected from O and N, the carbocyclic or heterocyclic group being optionally substituted with one or two substituents R.'}5. A compound according to claim 4 , or a salt claim 4 , N-oxide or tautomer thereof claim 4 , wherein Ris ethyl.6. A compound according to claim 1 , or a salt claim 1 , N-oxide or tautomer thereof claim 1 , wherein Ris selected from hydrogen and a group Rwherein Ris selected from a Calkyl group optionally substituted with a substituent R; cyclohexyl substituted with a substituent R; pyridine optionally substituted with a substituent R; and tetrahydroisoquinoline; wherein the substituent Ris selected from hydroxy; C(═O)NRR; piperidine; pyrrole and imidazole.7. A compound according to claim 6 , or a salt claim 6 , N-oxide or tautomer thereof claim 6 , wherein Ris a group Rwherein Ris a Calkyl group optionally substituted with a substituent R; wherein the substituent Ris selected from hydroxy and C(═O)NRR.8. A compound according to claim 6 , or a salt claim 6 , N-oxide or tautomer thereof claim 6 , wherein Ris hydrogen.9. A compound according to claim 1 , or a salt claim 1 , N-oxide or tautomer thereof claim 1 , wherein Ris fluorine.10. A compound according to claim 1 , or a salt claim 1 , N ...

DUAL NAV1.2/5HT2a INHIBITORS FOR TREATING CNS DISORDERS

Compounds of formula I: 2. A compound according to wherein Q is an optionally substituted nitrogenous aliphatic monocycle chosen from pyrrolidine claim 1 , piperidine claim 1 , morpholine claim 1 , piperazine claim 1 , azepane claim 1 , oxazepane claim 1 , thiazapane and diazepane.34-. (canceled)5. A compound according to wherein Q is an optionally substituted nitrogenous aliphatic bicycle chosen from diazabicycloheptane and diazabicyclooctane.6. (canceled)7. A compound according to wherein Q is an optionally substituted nitrogenous aliphatic spirocycle chosen from diazaspiro[4.4]nonane and diazaspiro[4.5]decane.8. (canceled)9. A compound according to wherein Q is an optionally substituted nitrogenous aliphatic spirocycle chosen from oxazaspiro[3.4]octane claim 1 , oxazaspiro[3.4]octene claim 1 , azaspiro [4.4]nonane claim 1 , and oxazaspiro [4.5]decane.10. (canceled)13. A compound according to wherein Ris an optionally substituted monocycle chosen from benzene claim 1 , cyclohexane claim 1 , tetrahydropyridazine and tetrahydropyran.14. A compound according to wherein Ris an optionally substituted fused bicycle containing an aromatic 6-membered ring and a non-aromatic 5-membered ring.15. (canceled)17. A compound according to wherein Ris an optionally substituted fused bicycle containing an aromatic 6-membered ring and a non-aromatic 6-membered ring.18. (canceled)19. A compound according to wherein Ris an optionally substituted fused bicycle containing two aromatic 6-membered rings.20. (canceled)21. A compound according to wherein Ris an optionally substituted fused bicycle containing an aromatic 6-membered ring and a non-aromatic 7-membered ring.2226-. (canceled)27. A compound according to wherein Lis —O—CHCH(OH)CH—.2829-. (canceled)30. A compound according to wherein Lis —CH—.3132-. (canceled)33. A compound according to wherein Lis —CHCH—.3435-. (canceled)36. A compound according to wherein Lis —OCHCH—.37. (canceled)38. A compound according to wherein Ris chosen ...

HYDROGEN SULFIDE DONOR IN ORGANIC SALT FORM AND PREPARATION METHOD THEREFOR

A hydrogen sulfide donor in an organic salt form and a preparation method thereof. The hydrogen sulfide donor exists as a salt formed by organic compounds with an alkaline motif and hydrogen sulfide with weak acidity. The hydrogen sulfide donor features with a simple structure, and an easy preparation method. Moreover, hydrogen sulfide donors in different forms can be prepared according to research and development needs. After the hydrogen sulfide donor enters an organism, the process of in vivo dissociation and hydrogen sulfide supply is simple, rapid, and effective, and there is no requirement for enzyme or any other complicated condition, and thus, the hydrogen sulfide donor has a great application prospect and value. 1. A hydrogen sulfide donor in organic salt form , characterized in that the donor is a salt structure formed by organic compounds with basic moiety and hydrogen sulfide.2. The hydrogen sulfide donor in organic salt form according to claim 1 , characterized in that said organic compounds having basic moiety are those pharmacological compounds possessing physiological and/or pharmacological activities.3. The hydrogen sulfide donor in organic salt form according to claim 1 , characterized in that said organic compounds having basic moiety are those with the structures selected from the group consisting of guanidines claim 1 , amidines claim 1 , hydrazines.4. The hydrogen sulfide donor in organic salt form according to claim 1 , characterized in that said organic compounds having basic moiety are those amino acid compounds such as arginine claim 1 , lysine claim 1 , etc.5. The hydrogen sulfide donor in organic salt form according to claim 1 , characterized in that said organic compounds having basic moiety are alkaloids.6. A preparative method for hydrogen sulfide donor in organic salt form according to claim 1 , characterized in that said organic compounds having basic moiety are dissolved in the solvent claim 1 , to which is added hydrogen sulfide ...

Apparatus and Process for the Automated Chemical Synthesis of Compounds

Provided is an apparatus for the automated synthesis of at least one chemical compound including: at least one cartridge including at least one first compartment for providing at least one first reagent for the chemical synthesis of the at least one compound; at least one second compartment for providing at least one second reagent for the chemical synthesis of the at least one compound, and at least one third compartment for purifying the at least one synthesized compound; at least one reaction container for providing the compounds to be fed into at least one of the compartments of the cartridge and/or collecting the reaction product from at least one of the compartments of the cartridge; at least one solvent container; at least two flow patch selecting valve and at least one pump. 1. An apparatus for the automated synthesis of at least one chemical compound , comprising:at least one cartridge comprising:at least one first compartment for providing at least one first reagent for the chemical synthesis of the at least one compound;at least one second compartment for providing at least one second reagent for the chemical synthesis of the at least one compound, andat least one third compartment for purifying the at least one synthesized compound;at least one reaction container for providing the compounds to be fed into at least one of the compartments of the cartridge and/or collecting the reaction product from at least one of the compartments of the cartridge;at least one solvent container for storing solvent systems used for at least one of the compartments of the cartridge;optionally at least one waste container for collecting the waste from at least one of the compartments of the cartridge;at least two flow patch selecting valves, wherein at least one first valve selects the liquid source and at least one second valve directs the liquid to one of the compartments in the cartridge, reaction container or optional waste container, andat least one pump arranged ...

PVC Plasticizers and Methods for Making Thereof

A plasticized PVC composition free of phthalate is disclosed. The composition comprises a tertiary diamide plasticizer prepared from biorenewable feedstock such as fatty acid selected from tall oil fatty acids, tall oil fatty acid monomers, fatty acids derived from tall oil fatty acid, and mixtures thereof. The tertiary diamide plasticizer is a reaction product of a reactant mixture comprising the fatty acid and one or more monocyclic diamines.

Salt forms of [R-(R*,R*)]-2-(4-fluorophenyl)-beta, delta-dihydroxy-5-(1-methylethyl)-3-phenyl-4-[(phenylamino)carbonyl]-1H-pyrrole-1-heptanoic acid

Novel salt forms of [R—(R*,R*)]-2-(4-fluorophenyl)-β,δ-dihydroxy-5-(1-methylethyl)-3-phenyl-4-[(phenylamino)carbonyl]-1H-pyrrole-1-heptanoic acid characterized by their X-ray powder diffraction pattern and solid-state NMR spectra are described, as well as methods for the preparation and pharmaceutical composition of the same, which are useful as agents for treating hyperlipidemia, hypercholesterolemia, osteoporosis, benign prostatic hyperplasia, and Alzheimer's Disease. 1. An atorvastatin ammonium or hydrate thereof having an x-ray powder diffraction pattern containing the following 2θ peaks measured using CuK radiation: 7.8 , 8.8 , 9.3 , 9.9 , 10.6 , 12.4 , and 19.5.2. (canceled)3. (canceled)4. (canceled)5. (canceled)6. (canceled)7. (canceled)8. (canceled)9. An atorvastatin erbumine or hydrate thereof having an x-ray powder diffraction pattern containing the following 2θ peaks measured using CuK radiation: 5.4 , 7.3 , 9.5 , 17.8 , 19.2 , 20.0 , 22.2 , and 24.2 , or a solid state F nuclear magnetic resonance having the following chemical shifts expressed in parts per million: −110.4.10. An atorvastatin L-lysine or hydrate thereof having an x-ray powder diffraction pattern containing the following 2θ peaks measured using CuK radiation: 6.7 , 9.8 , 17.1 , and 24.0.11. (canceled)12. An atorvastatin olamine or hydrate thereof having an x-ray powder diffraction pattern containing the following 2θ peaks measured using CuK radiation: 8.5 , 9.8 , 17.4 , 18.6 , 20.9 , 22.5 , and 24.1 , or a solid state F nuclear magnetic resonance having the following chemical shifts measured in parts per million: −118.7.13. An atorvastatin piperazine or hydrate thereof having an x-ray powder diffraction pattern containing the following 2θ peaks measured using CuK radiation: 7.8 , 9.3 , 11.8 , 16.1 , and 19.7.14. An atorvastatin sodium or hydrate thereof having an x-ray powder diffraction pattern containing the following 2θ peaks measured using CuK radiation: 3.4 , 4.9 , 7.6 , 8.0 , 9.9 , 18 ...

Salt forms of [R-(R*,R*)]-2-(4-fluorophenyl)-beta,delta-dihydroxy-5-(1-methylethyl)-3-phenyl-4-[(phenylamino)carbonyl]-1H-pyrrole-1-heptanoic acid

Novel salt forms of [R—(R*,R*)]-2-(4-fluorophenyl)-β,δ-dihydroxy-5-(1-methylethyl)-3-phenyl-4-[(phenylamino)carbonyl]-1H-pyrrole-1-heptanoic acid characterized by their X-ray powder diffraction pattern and solid-state NMR spectra are described, as well as methods for the preparation and pharmaceutical composition of the same, which are useful as agents for treating hyperlipidemia, hypercholesterolemia, osteoporosis, benign prostatic hyperplasia, and Alzheimer's Disease.

Catalytic Hydrogenation for the Preparation of Amines from Amide Acetals, Ketene N,O-Acetals or Ester Imides

The present invention relates to a process for the preparation of amines, comprising the following steps: Reaction of a (i) amide acetal of the general formula (I), or (ii) ketene N,O-acetal of the general formula (II), or (iii) ester imide of the general formula (III) with H 2 in the presence of a hydrogenation catalyst, where catalyst and amide acetal or ketene N,O-acetal or ester imide are used in a molar ratio of from 1:10 to 1:100 000 and where a hydrogen pressure of from 0.1 bar to 200 bar is established and where a temperature in the range of from 0° C. to 250° C. is established.

ORGANO-1-OXA-4-AZONIUM CYCLOHEXANE COMPOUNDS

Novel 1-oxa-4-azonium cyclohexane salts are described. These compounds can be used as structure directing agents, and they overcome many of the typical problems associated with OSDA synthesis and subsequent zeolite synthesis. Methods for synthesis of the 1-oxa-4-azonium cyclohexane salts from a variety of starting materials are also described. A substituted hydrocarbon is added to water to form a mixture, and a 1-oxa-4-azacyclohexane derivative is then added. The reaction mixture stirred until a solution containing the 1-oxa-4-azonium cyclohexane salt is obtained. 1. A morpholinium compound comprising: {'chemistry': {'@id': 'CHEM-US-00001', '@num': '00001', 'img': {'@id': 'EMI-C00001', '@he': '19.47mm', '@wi': '31.24mm', '@file': 'US20180258058A1-20180913-C00001.TIF', '@alt': 'embedded image', '@img-content': 'chem', '@img-format': 'tif'}}, 'br': None, 'sub': 1', '2', '3', '4', '9', '10', '5', '6', '7', '8, 'sup': +', '−, '2-R-2-R-3-R-3-R-4-R-4-R-5-R-5-R-6-R-6-R-1-oxa-4-azoniumcyclohexane-X,\u2003\u2003Formula 1, 'a 1-oxa-4-azonium cyclohexane salt having a structure of{'sub': 1', '9', 'n', '2n+1', '10', 'n', '2n+1', 'p', '2p−1, 'wherein R-Rare independently selected from H or an alkyl group having the formula CH, Ris selected from an alkyl group having the formula CHwhere n is in the range from 1 to 4, benzyl, 1-methylnaphthalene, 2-methylnaphthalene and a non-olefinic alkyl group having the formula CHwhere p is in the range from 4 to 10, X is halide or hydroxide, and the total number of C atoms in the molecule is in the range of 4 to 16;'}or combinations thereof.2. The morpholinium compound of wherein X is hydroxide.3. The morpholinium compound of wherein R-Rare H.4. The morpholinium compound of wherein at least one of Rand Ris the alkyl group having the formula CH.5. The morpholinium compound of wherein at least one of R-Ris an alkyl group.6. The morpholinium compound of wherein at least one of Rand Ris an alkyl group having the formula CH.7. The morpholinium ...

Catalytic Hydrogenation for Producing Amines from Carboxylic Acid Amides, Carboxylic Acid Diamides, Di-, Tri-, or Polypeptides, or Peptide Amides

The present invention relates to a process for the preparation of amines, comprising the following steps: a. reaction of a (i) carboxylic acid amide of the general formula (I), or (ii) carboxylic acid diamide of the general formula (II), or (iii) di-, tri- or polypeptide, or (iv) peptide amide with carboxy-terminal amide function with an alkylating agent, b. addition of a hydrogenation catalyst to the reaction mixture in a molar ratio of from 1:10 to 1:100 000, based on carboxylic acid amide, carboxylic acid diamide, di-, tri- or polypeptide or peptide amide, c. reaction of the reaction mixture with hydrogen, where a hydrogen pressure of from 0.1 bar to 200 bar is established and where a temperature in a range of from 0° C. to 250° C. is established. 110-. (canceled)12. The process of claim 11 , wherein the alkylating agent is selected from the group consisting of: alkyl halides; esters of sulphonic acid; esters of fluorosulphonic acid; esters of trifluoromethanesulphonic acid; esters of chloroformic acid; oxonium salts; dialkyl sulphates; and diazomethane.13. The process of claim 11 , wherein the hydrogenation catalyst comprises at least one active metal.14. The process of claim 13 , wherein the active metal is a metal of group VII B and/or VIII B of the Periodic Table of the Elements.15. The process of claim 11 , wherein claim 11 , after step a) claim 11 , a base is added to the reaction mixture and wherein a molar ratio of base to alkylating agent of from 1:1 to 1:3 is produced.16. The process of claim 11 , wherein the reaction is carried out in a solvent.17. The process of claim 16 , wherein the solvent is selected from the group consisting of: hydrocarbons; chlorinated hydrocarbons; ethers; esters; and alcohols.18. The process of claim 11 , wherein the reaction is carried out without solvents.19. The process of claim 16 , wherein said alkylating agent is anhydrous and is selected from the group consisting of: carboxylic acid amide; carboxylic acid diamide; a di ...

ORGANO-1-OXA-4-AZONIUM CYCLOHEXANE COMPOUNDS

Novel 1-oxa-4-azonium cyclohexane salts are described. These compounds can be used as structure directing agents, and they overcome many of the typical problems associated with OSDA synthesis and subsequent zeolite synthesis. Methods for synthesis of the 1-oxa-4-azonium cyclohexane salts from a variety of starting materials are also described. A substituted hydrocarbon is added to water to form a mixture, and a 1-oxa-4-azacyclohexane derivative is then added. The reaction mixture stirred until a solution containing the 1-oxa-4-azonium cyclohexane salt is obtained. 1. A morpholinium compound comprising a 1-oxa-4-azonium cyclohexane salt having a structure of:{'chemistry': {'@id': 'CHEM-US-00001', '@num': '00001', 'img': {'@id': 'EMI-C00001', '@he': '25.91mm', '@wi': '61.64mm', '@file': 'US20180265485A1-20180920-C00001.TIF', '@alt': 'embedded image', '@img-content': 'chem', '@img-format': 'tif'}}, 'br': None, 'sub': 1', '2', '3', '4', '9', '10', '5', '6', '7', '8, 'sup': +', '−, '2-R-2-R-3-R-3-R-4-R-4-R-5-R-5-R-6-R-6-R-1-oxa-4-azoniumcyclohexane-X,'}{'sub': 1', '8', 'n', '2n+1', '1', '8', '9', '10', 'm', '2m, 'wherein R-Rare independently selected from H or an alkyl group having the formula CHwhere n is in the range from 1 to 4; at least one of R-Ris an alkyl group; Rand Rform a cyclic alkyl group having the formula CHforming a heterocycle of ring size q, where m is in the range from 4 to 8, and q is in the range of 5 to m+1; X is hydroxide; and the total number of C atoms in the molecule is in a range of 8 to 17.'}2. The morpholinium compound of having the Formula 1 claim 1 , wherein at least two of R-Rare an alkyl group.3. The morpholinium compound of having the Formula 1 claim 1 , wherein at least two of R-Rare an alkyl group claim 1 , and wherein at least two of R-Rare the same alkyl group.4. The morpholinium compound of having the Formula 1 claim 1 , wherein the at least two of R-Rare Rand R claim 1 , or Rand R claim 1 , or Rand R claim 1 , or Rand R.5. A ...

ORGANO-1-OXA-4-AZONIUM CYCLOHEXANE COMPOUNDS

Novel 1-oxa-4-azonium cyclohexane salts are described. These compounds can be used as structure directing agents, and they overcome many of the typical problems associated with OSDA synthesis and subsequent zeolite synthesis. Methods for synthesis of the 1-oxa-4-azonium cyclohexane salts from a variety of starting materials are also described. A substituted hydrocarbon is added to water to form a mixture, and a 1-oxa-4-azacyclohexane derivative is then added. The reaction mixture stirred until a solution containing the 1-oxa-4-azonium cyclohexane salt is obtained. 2. The morpholinium compound of wherein X is hydroxide.3. The morpholinium compound of wherein R-Rare H.4. The morpholinium compound of wherein at least one of R-Ris an alkyl group.5. The morpholinium compound of wherein x is 1 claim 1 , and y is m.6. The morpholinium compound of wherein when Ris an alkyl group and X is hydroxide.7. The morpholinium compound of wherein Ris an alkyl group and n is 1 claim 1 , m is 4 claim 1 , x is 1 claim 1 , and y is 4.8. The morpholinium compound of wherein at least two of R-Rare the alkyl group claim 1 , and wherein the at least two of R-Rare Rand R claim 1 , or Rand R claim 1 , or Rand R claim 1 , or Rand R.9. The morpholinium compound of wherein at least two of R-Rare an alkyl group claim 1 , and wherein at least two of R-Rare the same alkyl group.10. A method for synthesizing a 1-oxa-4-azonium cyclohexane salt claim 1 , comprising:preparing an aqueous mixture comprising water, a substituted hydrocarbon, and a 1-oxa-4-azacyclohexane derivative;reacting the aqueous mixture;obtaining a solution comprising the 1-oxa-4-azonium cyclohexane salt; andwherein the mixture and the solution are essentially free of aluminum and silicon. This application is a Continuation-In-Part of copending U.S. application Ser. No. 15/334,154 filed Oct. 25, 2016, which application is a Division of U.S. application Ser. No. 14/561,132 filed Dec. 4, 2014, now U.S. Pat. No. 9,522,896 issued Dec. 20 ...

Synergistic compositions

The present invention describes a synergistic composition comprising of one or more statins, or one or more dipeptidyl peptidase IV (DPP IV) inhibitor or one or more biguanide antihyperglycaemic agent and a PPAR agonist of formula (Ia) for the treatment of diabetes, especially non-insulin dependent diabetes (NIDDM) or Type 2 diabetes and conditions associated with diabetes mellitus and to compositions suitable for use in such method. The invention also describes the preparation of such compositions. The present invention also relates to certain novel salts of the PPAR agonist of formula (I), processes for the preparation of these novel salts and use thereof.

SYNERGISTIC COMPOSITIONS

The present invention describes a synergistic composition comprising of one or more statins, or one or more dipeptidyl peptidase IV (DPP IV) inhibitor or one or more biguanide antihyperglycaemic agent and a PPAR agonist of formula (1a) for the treatment of diabetes, especially non-insulin dependent diabetes or Type 2 diabetes and conditions associated with diabetes mellitus and to compositions suitable for use in such method. The invention also describes the preparation of such compositions. The present invention also relates to certain novel salts of the PPAR agonist of formula (I), processes for the preparation of: these novel salts and use thereof.

Bioconjugation of Polypeptides

Certain embodiments of the present invention relate to methods of forming and manipulating bioconjugates. Particularly, but not exclusively certain embodiments relate to methods of reversible carbon-carbon bond bioconjugation using aldol based chemical reactions at physiological conditions. 169-. (canceled)71. A method according to claim 70 , wherein the catalyst molecule comprises a secondary amine moiety or an acid addition salt thereof.72. A method according to claim 71 , wherein the catalyst molecule comprises a cyclic secondary amine molecule.74. A method according to claim 72 , wherein the catalyst molecule comprises a substituted cyclic secondary amine molecule claim 72 , wherein optionally the substituted cyclic secondary amine molecule is substituted pyrrolidine or wherein the catalyst molecule comprises a tetrazole-substituted cyclic molecule claim 72 , wherein optionally the tetrazole-substituted cyclic molecule is pyrrolidine substituted with tetrazole e.g. 2S-tetrazolylpyrrolidine.75. The method according to claim 70 , which comprises contacting the first polypeptide claim 70 , the aldehyde donor molecule and the catalyst molecule in a buffer solution having a pH of between about 7 and 8 and/or at a temperature of between about 35° C. and about 38° C.76. The method according to claim 70 , wherein the first polypeptide comprises the first aldehyde moiety at an internal sequence of the first polypeptide; at a terminal loop claim 70 , a C-terminus claim 70 , or an N-terminus of the first polypeptide; on a solvent-accessible region of the first polypeptide when folded; and/or at a site of post-translational modification of the first polypeptide that is native or non-native to the amino acid sequence of the first polypeptide.77. The method according to claim 70 , wherein the aldehyde donor moiety further comprises a functional moiety and the method comprises incorporating the functional moiety into the second polypeptide.78. The method according to claim 77 ...

Base generator, reagent, organic salt, composition, method for manufacturing device, cured film and device

A curing agent or a curing accelerator which is easy to synthesize and may cure an epoxy resin and the like, or may accelerate the curing is provided. A curing agent or a curing accelerator according to some embodiments of the present invention has a highly-coordinated silicon structure.

METHOD FOR THE MANUFACTURING OF 2-(3-(ALKYL AND ALKENYL)MORPHOLINO)-ETHAN-1-OLS

The present invention relates to a method for the manufacture of 2-(3-(alkyl or alkenyl)morpholino)-ethan-1-ols by reduction of 8a-(alkyl and alkenyl)hexahydrooxazolo[2,3-c][1,4]oxazines encompassing a process for producing 2-(3-(4-propylheptyl)morpholino)ethan-1-ol with the INN name delmopinol. The invention also relates to 1-chloro-4-propylhept-3-ene, 1-iodo-4-propylhept-3-ene, 8a-(4-5 propylheptyl)hexahydrooxazolo[2,3-c][1,4]oxazine, 8a-(4-propylhept-3-en-1-yl)hexahydrooxazolo[2,3-c][1,4]oxazine and 2-(3-(4-propylhept-3-en-1-yl)morpholino)ethan-1-ol which are intermediates in the delmopinol process. 3. The process according to claim 2 , wherein compound (II′) is 8a-4-propylhept-3-en-1-yl-hexahydrooxazolo[2 claim 2 ,3-c][1 claim 2 ,4]oxazine and said reduction in step iii) is performed by catalytic hydrogenation.4. The process according to claim 2 , wherein compound (II′) is 8a-4-propylheptyl-hexahydrooxazolo[2 claim 2 ,3-c][1 claim 2 ,4]oxazine and said reduction in step iii) is performed by catalytic hydrogenation or by treatment with a metal borohydride.5. The process according to wherein compound (II′) is 8a-4-propylhept-3-en-1-yl-hexahydrooxazolo[2 claim 2 ,3-c][1 claim 2 ,4]oxazine and said reduction in step iii) proceeds through 2-(3-(4-propylhept-3-en-1-yl)morpholino)ethan-1-ol.6. The process according to claim 1 , wherein X is selected from the group consisting of Cl and Br.7. The process according to claim 1 , wherein said strong base used in step i) is selected from the group consisting of metal hydrides claim 1 , metal alkoxides claim 1 , metal amides claim 1 , organolithium reagents and organomagnesium reagents.8. The process according to claim 7 , wherein said strong base is lithium hydride9. The process according to claim 1 , wherein said strong base in step i) is used in 0.95-1.05 molar equivalents relative to 4-(2-hydroxyethyl)morpholin-3-one.10. The process according to claim 1 , wherein the reaction in step ii) is performed at a temperature of − ...

Method for depleting 2-methoxyethanol (moe)

A process for the depletion of 2-methoxyethanol (MOE) from a mixture comprising predominantly morpholine (MO) (crude morpholine), wherein crude morpholine is distilled in a distillation column in the presence of an alkali metal compound of the general formula M + [RO − ] (M + is alkali metal cation and R is hydrogen (H), methyl, ethyl, propyl, isopropyl, n-butyl, isobutyl, sec-butyl or tert-butyl), where MO and a compound of the general formula R—OH are distilled off and an alkali metal methoxyethoxide of the general formula M + [MeOEtO − ] is obtained in the bottom of the column.

Catalyst and method for producing an amine

The invention relates to a method for producing an amine by reacting a primary or secondary alcohol, aldehyde and/or ketone with hydrogen and a nitrogen compound, selected from the group containing ammonia and primary and secondary amines, in the presence of a supported catalyst that contains copper, nickel and cobalt. According to the invention, the catalytically active mass of the catalyst, prior to the reduction of the same using hydrogen, contains oxygen-containing compounds of aluminium, copper, nickel and cobalt and an amount ranging between 0.2 and 5.0 wt. % of oxygen-containing compounds of tin, calculated as SnO. The invention also relates to catalysts defined as above.

PROCESS FOR THE PRODUCTION OF 2 (3 ALCHILMORPHOLIN) -ETAN-1-OLO

一种无卤阻燃剂的制备方法及其阻燃聚烯烃组合物

本发明公开了一种无卤阻燃剂的制备方法及其阻燃聚烯烃组合物，属于阻燃剂制备领域。其中，二磷酸哌嗪的制备方法为使按比例的磷酸和哌嗪反应后，通过喷雾干燥处理制备得到二磷酸哌嗪；焦磷酸哌嗪的制备方法为结合上述二磷酸哌嗪的制备方法，将得到的二磷酸哌嗪在隋性气氛或真空条件下进行脱水缩合反应后得到。本发明还提供了一种阻燃聚烯烃组合物，该组合物包括100质量份的聚烯烃树脂、10~100质量份所述方法制备的焦磷酸哌嗪等。所述制备方法制备二磷酸哌嗪的收率>95%，焦磷酸哌嗪具有>90的以W值表示的白度。所述阻燃聚烯烃组合物具有优良的阻燃性能，焦磷酸哌嗪的添加量少，且具有优异的着色性能，具有极佳的工业应用前景。

Bicyclosubstituted azopyrazolone derivatives salts, method for preparing and using them

FIELD: medicine, pharmaceutics. SUBSTANCE: invention refers to pharmaceutically acceptable salts specified in a group consisting of sodium salt, lithium salt, potassium salt, calcium salt, magnesium salt, arginine salt, lysine salt, methanamine salt, dimethylamine salt, trimethylamine salt, ethylamine salt, diethylaminte salt, triethylamine salt, ethanolamine salt, piperazine salt, dibenzylethylene diamine salt, methyl glucamine salt, tromethamine salt, quaternary tetramethylammonium salt, quaternary tetraethylammonium salt and choline salt, bicyclosubstituted azopyrazole derivatives of general formula . The invention also refers to a method for preparing them, a pharmaceutical composition containing them, and using them as a therapeutic agent, particularly as thrombopoietin (TPO) mimetics, using them as TPO agonists. In general formula (I), Het is specified in a group consisting of phenyl, furanyl and thienyl; each R 1 , R 2 , R 3 and R 4 are independently specified in a group consisting of hydrogen and alkyl; n is equal to 0, 1 or 2. EFFECT: improving the pharmokinetic properties of the compound of formula (I) ensured by better solubility. 19 cl, 1 tbl, 25 ex РОССИЙСКАЯ ФЕДЕРАЦИЯ ФЕДЕРАЛЬНАЯ СЛУЖБА ПО ИНТЕЛЛЕКТУАЛЬНОЙ СОБСТВЕННОСТИ (12) ОПИСАНИЕ (21)(22) Заявка: (19) RU (11) (13) 2 538 977 C2 (51) МПК C07D 231/46 (2006.01) C07D 405/12 (2006.01) C07D 409/12 (2006.01) A61K 31/4152 (2006.01) A61K 31/4155 (2006.01) A61K 31/655 (2006.01) A61P 7/04 (2006.01) ИЗОБРЕТЕНИЯ К ПАТЕНТУ 2011153934/04, 28.05.2010 (24) Дата начала отсчета срока действия патента: 28.05.2010 Приоритет(ы): (30) Конвенционный приоритет: (43) Дата публикации заявки: 20.07.2013 Бюл. № 20 (45) Опубликовано: 10.01.2015 Бюл. № 1 (73) Патентообладатель(и): ЦЗЯНСУ ХЭНЖУЙ МЕДИЦИН КО., ЛТД. (CN), ШАНХАЙ ХЭНЖУЙ ФАРМАСЬЮТИКАЛ СО., ЛТД. (CN) 10.01.2008. RU 2284994 С2, 10.10.2006. WO 01/ 89457 A2, 29.11.2001 (85) Дата начала рассмотрения заявки PCT на национальной фазе: 11.01.2012 (86) Заявка PCT: 2 5 3 8 9 7 7 ...

Sphyngosine kinase inhibitors

FIELD: medicine, pharmaceutics. SUBSTANCE: present invention refers to new compounds of formula I or their pharmaceutically acceptable salts showing an ability to inhibit sphingosine kinase, to a based pharmaceutical composition, to a method of inhibiting sphingosine kinase and a method of treating diseases specified in breast cancer, diabetic retinopathy, arthritis and colitis. , wherein X represents -C(R 3 ,R 4 )N(R 5 )-, -C(O)N(R 4 )-; R 1 represents phenyl unsubstituted or substituted by 1 or 2 halogens. The values of R 2 , R 3 , R 4 , R 5 substitutes are such as specified in the patent claim. EFFECT: preparation of new compounds. 17 cl, 24 dwg, 9 tbl, 26 ex РОССИЙСКАЯ ФЕДЕРАЦИЯ (19) RU (11) 2 447 060 (13) C2 (51) МПК C07C C07C C07C C07C C07D C07D C07D ФЕДЕРАЛЬНАЯ СЛУЖБА ПО ИНТЕЛЛЕКТУАЛЬНОЙ СОБСТВЕННОСТИC07D C07D C07D 233/57 255/44 317/32 323/23 317/58 207/02 295/13 295/32 213/24 265/30 (2006.01) (2006.01) (2006.01) (2006.01) (2006.01) (2006.01) (2006.01) (2006.01) (2006.01) (2006.01) C07D C07D C07D C07D C07D C07D C07D A61K A61K A61K 233/54 (2006.01) 277/46 (2006.01) 263/58 (2006.01) 277/82 (2006.01) 257/04 (2006.01) 209/88 (2006.01) 473/34 (2006.01) 31/33 (2006.01) 31/16 (2006.01) 31/13 (2006.01) (см. прод.) (12) ОПИСАНИЕ ИЗОБРЕТЕНИЯ К ПАТЕНТУ Приоритет(ы): (30) Конвенционный приоритет: 17.06.2005 US 60/691,563 (73) Патентообладатель(и): ЭПОУДЖИ БИОТЕКНОЛОДЖИ КОРПОРЕЙШН (US) 2 4 4 7 0 6 0 (43) Дата публикации заявки: 27.07.2009 Бюл. № 21 2 4 4 7 0 6 0 R U (56) Список документов, цитированных в отчете о поиске: US 4053509 А, 11.10.1977. US 5595995 А, 21.01.1997. US 4332806 А, 01.06.1982. US 3663565 A, 16.05.1972. US 4349552 A, 14.09.1982. US 6649600 B1, 18.11.2003. US 3657273 A, 18.04.1972. WO 99/26927 A2, 03.06.1999. WO 2004/089470 A2, 21.10.2004. SU 1574586 A1, 30.06.1990. SU 1367194 A1, 10.04.1996. RU 2197467 C2, 27.01.2003. SU 451691 A, 09.07.1975. (см. прод.) C 2 C 2 (45) Опубликовано: 10.04.2012 Бюл. № 10 (85) Дата начала рассмотрения заявки PCT на ...

Polyolefin Composition

AMIDES OF δ-AMINO-γ-HYDROXY-ω-ARYLALCANE ACID

FIELD: medicine, pharmaceutics. SUBSTANCE: invention relates to amide of δ-amino-γ-hydroxy-ω-arylalcane acid of formula and its pharmaceutically acceptable salts. Also described are pharmaceutical compositions, which include said compounds, and application of said compounds for preparation of medication, intended for treatment of pathological states, associated with renin activity, in particular for treatment of hypertension. EFFECT: obtaining pharmaceutically acceptable salts, which possess rennin-inhibiting ability. 21 cl, 161 ex РОССИЙСКАЯ ФЕДЕРАЦИЯ (19) RU (11) 2 413 716 (51) МПК C07C C07C C07C C07C C07C C07D ФЕДЕРАЛЬНАЯ СЛУЖБА C07D ПО ИНТЕЛЛЕКТУАЛЬНОЙ СОБСТВЕННОСТИ, C07D ПАТЕНТАМ И ТОВАРНЫМ ЗНАКАМ C07D C07D (12) ОПИСАНИЕ 237/20 237/24 255/50 255/60 271/24 295/027 307/79 313/08 319/18 333/08 (2006.01) (2006.01) (2006.01) (2006.01) (2006.01) (2006.01) (2006.01) (2006.01) (2006.01) (2006.01) A61K A61K A61K A61K A61K A61K A61K A61K A61K A61P (13) C2 31/165 (2006.01) 31/275 (2006.01) 31/325 (2006.01) 31/343 (2006.01) 31/357 (2006.01) 31/381 (2006.01) 31/402 (2006.01) 31/44 (2006.01) 31/5375 (2006.01) 9/12 (2006.01) ИЗОБРЕТЕНИЯ К ПАТЕНТУ (21)(22) Заявка: 2006122636/04, 25.11.2004 (24) Дата начала отсчета срока действия патента: 25.11.2004 (73) Патентообладатель(и): НОВАРТИС АГ (CH) R U Приоритет(ы): (30) Конвенционный приоритет: 26.11.2003 US 60/525,374 (72) Автор(ы): БЭШЛИН Даниель Каспар (CH), МАЙБАУМ Юрген Клаус (DE), ЗЕЛЛЬНЕР Хольгер (CH) (43) Дата публикации заявки: 27.01.2008 Бюл. № 3 2 4 1 3 7 1 6 2 4 1 3 7 1 6 R U (56) Список документов, цитированных в отчете о поиске: SU 1651786 A3, 23.05.1991. EP 0678503 A1, 25.10.1995. WO 0240007 A1, 23.05.2002. Wood J. M. et al "STRUCTURE-BASED DESIGN OF ALISKIREN, A NOVEL ORALLY EFFECTIVE RENIN INHIBITOR" BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 2003, Vol:308, Nr:4, Page(s): 698-705. Goschke R. et al "DESING AND SYNTHESIS OF NOVEL 2,7-DIALKYL SUBSTITUTED (см. прод.) C 2 C 2 (45) Опубликовано: 10.03.2011 Бюл. ...

Salts of bicyclo-substituted derivatives of azopirazole, a method for their production and use

1. Фармацевтически приемлемые соли соединения формулы (I)где Het выбран из группы, состоящей из фенила, фурила и тиенила;R, R, Rи Rкаждый независимо выбран из группы, состоящей из водорода и алкила;n равно 0, 1 или 2; исоли представляют собой соли присоединения основания.2. Фармацевтически приемлемые соли по п.1, где они представляют собой соли соединения формулы (IA)где Het выбран из группы, состоящей из фенила, фурила и тиенила;R, R, Rи Rкаждый независимо выбран из группы, состоящей из атома водорода и алкила;М выбран из группы, состоящей из иона металла, иона аммония и основной аминокислоты;m равно 1 или 2;n равно 0, 1 или 2; исоли представляют собой соли присоединения основания.3. Фармацевтически приемлемые соли по п.1 или 2, где соли выбраны из группы, состоящей из соли натрия, соли лития, соли калия, соли кальция, соли магния, соли аргинина, соли лизина, соли метанамина, соли диметиламина, соли триметиламина, соли этиламина, соли диэтиламина, соли триэтиламина, соли этаноламина, соли пиперазина, соли дибензилэтилендиамина, соли меглумина, соли трометамина, соли четвертичного тетраметиламмония, соли четвертичного тетраэтиламмония и соли холина, предпочтительно соли диэтиламина, соли этаноламина, соли холина, соли пиперазина, соли меглумина и соли трометамина, более предпочтительно соли этаноламина, соли холина, соли меглумина и соли трометамина, и наиболее предпочтительно соли этаноламина.4. Фармацевтически приемлемые соли по п.1, где соли выбраны из группы, состоящей из:5. Способ получения фармацевтически приемлемых солей по любому из пп.1-4, включающий следующие стадии:(а) растворение или суспендирование соединения формулы (I) в органич РОССИЙСКАЯ ФЕДЕРАЦИЯ (19) RU (11) (13) 2011 153 934 A (51) МПК A61K 31/655 (2006.01) ФЕДЕРАЛЬНАЯ СЛУЖБА ПО ИНТЕЛЛЕКТУАЛЬНОЙ СОБСТВЕННОСТИ (12) ЗАЯВКА НА ИЗОБРЕТЕНИЕ (21)(22) Заявка: 2011153934/04, 28.05.2010 (71) Заявитель(и): ЦЗЯНСУ ХЭНЖУЙ МЕДИЦИН КО., ЛТД. (CN), ШАНХАЙ ХЭНЖУЙ ФАРМАСЬЮТИКАЛ СО., ЛТД. (CN) Приоритет(ы): (30) ...

The method producing pyrrolidine

公开了一种通过使式(II)的1,4‑丁二醇(BDO)与氨在氢气和含金属的负载型催化剂存在下反应而生产式(I)的吡咯烷的方法，其特征在于该催化剂的催化活性物质在其用氢气还原之前含有铝、铜、镍和钴的含氧化合物以及以SnO计算为0.2‑5.0重量％的锡的含氧化合物，并且该反应在160‑220巴的绝对压力、160‑230℃的温度下以与所用BDO的摩尔比为5‑50使用氨并在相对于所用BDO的量为1.0‑4.5重量％的氢气存在下在液相中进行。

A kind of Azilsartan piperazine salt solvate and preparation method and application

本发明提供了一种阿齐沙坦哌嗪盐溶剂合物及其制备方法与应用，本发明阿齐沙坦哌嗪盐溶剂合物主要由阿齐沙坦、哌嗪和溶剂制备得到，晶型稳定，结晶度高，在水中不形成新的晶型，稳定性好，生物利用度高。本发明阿齐沙坦哌嗪盐溶剂合物的制备方法工艺简单，将阿齐沙坦和哌嗪在溶剂中反应，条件温和，能够得到晶型均一的阿齐沙坦哌嗪盐溶剂合物产品，适于大规模生产。本发明阿齐沙坦哌嗪盐溶剂合物的生物利用度高，是一种新型阿齐沙坦药用固体形式，可用于制备治疗高血压的药物，能够有效治疗高血压疾病。

Salt of 2-ring substituted pyrazolone azo derivatives, and preparation method and application thereof in medicaments

通式(I)所示的双环取代吡唑酮偶氮类衍生物药学上可接受的盐、其制备方法以及含有该药学上可接受盐的药物组合物、以及其作为治疗剂特别是作为血小板生成素(TPO)模拟物和血小板生成素受体激动剂的用途。

Compounds, compositions and methods of using same for modulating uric acid levels

本文中描述适用于调节血液尿酸含量的化合物、含有这些化合物的调配物以及其制备和使用方法。在一些实施例中，使用本文中描述的化合物治疗或预防与异常尿酸含量有关的病症。

Patent JPS4920974B1

Composition for removing a (photo)resist

본 발명은 전자회로 또는 표시소자를 패턴하는 레지스트(resist) 제거용 조성물에 관한 것으로, 아민 및 용제를 포함하는 레지스트 제거용 조성물에 있어서, 상기 아민이 고리형 아민 화합물인 것을 특징으로 하는 레지스트 제거용 조성물을 제공한다. 본 발명의 레지스트 제거용 조성물은 레지스트 제거력이 매우 우수하고, 패턴된 금속배선의 부식을 최소화 할 수 있는 장점이 있다. 레지스트 제거용 조성물, 고리형 아민 화합물

Tofenamic acid-piperazine salt type and preparation method thereof

本发明公开了一种托灭酸‑哌嗪盐型及其制备方法。本发明公开的托灭酸‑哌嗪盐型是由1个去质子化的甲灭酸和0.5个质子化的哌嗪构成不对称单元，其空间群为正交P bca晶系；其晶体学特征为： α＝β＝γ＝90°。本发明还公开了托灭酸‑哌嗪盐型的制备方法，将托灭酸和哌嗪加入到有机溶剂中，加热使其部分溶解并开始反应，获得悬浮液；将所得悬浮液搅拌反应，然后晶浆经过滤、用母液洗涤、干燥，获得托灭酸‑哌嗪盐型。该方法操作简单，重现性好，制备的盐型具有良好热力学稳定性和溶解性，其溶解度是托灭酸的3.79倍。

Polyphosphoric acid piperazine, preparation method and application thereof

本发明提供一种聚磷酸哌嗪、其制备方法及其应用。聚磷酸哌嗪的制备方法包括成盐步骤和老化步骤。成盐步骤包括哌嗪搅拌在5分钟～30分钟后缓慢加入预热到80℃～100℃的聚磷酸，保持温度45℃～65℃，搅拌反应0.5小时～3小时，得到聚磷酸哌嗪初产物。老化步骤包括抽真空至真空度为1000Pa～2000Pa，惰性气体置换多次并保持真空度，继续搅拌加热到150℃～200℃后，保持1小时～4小时，得到聚磷酸哌嗪。

Catalyst and method for producing an amine

本发明涉及一种制备胺的方法，包括使伯醇或仲醇、醛和/或酮与氢气及选自氨、伯胺和仲胺的氮化合物在含有铜、镍和钴的负载型催化剂存在下反应。根据本发明，所述催化剂的催化活性物质在用氢气将其还原之前包含铝、铜、镍和钴的氧化合物以及0.2-5.0重量%以SnO计的锡的氧化合物。本发明还涉及如上所定义的催化剂。

Cation-anionic complexes of palladium

FIELD: chemistry. SUBSTANCE: invention refers to chemistry and medicine, namely to new cation-anionic complexes of palladium. Complexes contain a protonated cation and a polynuclear anion of palladium. Cations used are protonated methylmorpholine [C 5 H 12 NO] + or 1-phenyl-2-methylaminopropanol [C 10 H 16 NO] + , and as anions, respectively – [PdCl 3 ] n 1- , where n is any integer, or [Pd 2 Cl 6 ] 2- . EFFECT: novel polynuclear complexes are characterized by low toxicity and exhibit high anti-tumor and radioprotective activity. 1 cl, 2 dwg, 6 tbl, 3 ex РОССИЙСКАЯ ФЕДЕРАЦИЯ (19) RU (11) (13) 2 699 809 C9 (51) МПК C07F 15/00 (2006.01) A61K 31/295 (2006.01) A61K 31/555 (2006.01) A61P 35/00 (2006.01) A61P 39/00 (2006.01) ФЕДЕРАЛЬНАЯ СЛУЖБА ПО ИНТЕЛЛЕКТУАЛЬНОЙ СОБСТВЕННОСТИ (12) СКОРРЕКТИРОВАННОЕ ОПИСАНИЕ ИЗОБРЕТЕНИЯ К ПАТЕНТУ Примечание: библиография отражает состояние при переиздании (52) СПК C07D 295/027 (2019.05); C07F 15/0066 (2019.05); A61K 31/295 (2019.05); A61K 31/555 (2019.05); A61P 35/00 (2019.05); A61P 39/00 (2019.05) (21)(22) Заявка: 2018134255, 27.09.2018 27.09.2018 (73) Патентообладатель(и): Общество с ограниченной ответственностью "Радифенс" (RU) (45) Опубликовано: 11.09.2019 (15) Информация о коррекции: Версия коррекции №1 (W1 C1) 2 6 9 9 8 0 9 C 9 07.02.2020 Бюл. № 4 Адрес для переписки: 192283, Санкт-Петербург, ул. Я. Гашека, 9, корп. 1, кв. 138, для Карпушенко Л.В. (54) Катионно - анионные комплексы палладия (57) Реферат: Изобретение относится к химии и медицине, а именно к новым катионно-анионным комплексам палладия. Комплексы содержат протонированный катион и полиядерный анион палладия. В качестве катионов используют протонированные метилморфолин [C5H12NO]+ R U или 1-фенил-2-метиламинопропанол [C10H16NO]+, а в качестве анионов, соответственно - [PdCl3]n1-, где n - любое целое число, или [Pd2Cl6]2-. Новые полиядерные комплексы характеризуются низкой токсичностью и проявляют высокую противоопухолевую и радиопротекторную активность. 1 з.п. ф-лы, 2 ил ...

Salt of aryl propionic acid compound and pharmaceutical application thereof

本发明提供了一种式Ⅰ化合物的碱加成盐、盐的晶型、制备方法，以及包含这些盐的药物组合物、制剂形式和制药用途。式Ⅰ化合物是一种属于芳基丙酸类的药学活性物质，以其为基础制备了新颖的盐型及其结晶形式，在水溶解性、溶出度、稳定性方面均好于式Ⅰ化合物。这些盐型及其结晶形式具有给药剂量小、药物起效快以及可以减小毒副作用和提高生物利用度等优点。含有式Ⅰ化合物的碱加成盐的药物组合物在制备镇痛、解热、消炎药物中具有广泛用途和广阔前景。

Bioconjugation of polypeptides

Certain embodiments of the present invention relate to methods of forming and manipulating bioconjugates. Particularly, but not exclusively certain embodiments relate to methods of reversible carbon-carbon bond bioconjugation using aldol based chemical reactions at physiological conditions.

Process for preparing substituted carboxylic acid ammonium salts

내용 없음

Piperidine preparation method

本发明公开了一种哌啶的制备方法，为采用改性分子筛催化剂催化气态戊二胺与气体稀释剂的混合气体制得所述哌啶，其中用于制备哌啶的改性分子筛催化剂包括质量百分比为90～99.9％的分子筛载体和质量百分比为0.1～10％的金属催化剂，所述金属催化剂负载于所述分子筛载体上。本发明通过控制混合气体中戊二胺的体积百分比浓度和质量空速，并采用一定的温度下通过上述的改性分子筛催化剂，即提高了哌啶的纯度、选择性和收率，又降低了生产成本，减少了环境污染，且工艺简单。

Use of compounds as energy materials

FIELD: power connections. SUBSTANCE: invention relates to the use of a compound having a crystal structure of the perovskite type ABX 3 as an energy material. Structural characteristics of the compound, such as alternating oxidative anions and reducing organic cations in space, providing connection with high efficiency of instantaneous energy release during detonation. Three-dimensional structure allows connection not only to have effect of energy material, but also to overcome disadvantages of existing energy materials. EFFECT: high stability of such a compound enables to obtain highly safe energy material with high detonation efficiency and high energy density. 42 cl, 25 dwg, 18 tbl, 11 ex РОССИЙСКАЯ ФЕДЕРАЦИЯ (19) RU (11) (13) 2 725 424 C2 (51) МПК C06B 49/00 (2006.01) ФЕДЕРАЛЬНАЯ СЛУЖБА ПО ИНТЕЛЛЕКТУАЛЬНОЙ СОБСТВЕННОСТИ (12) ОПИСАНИЕ ИЗОБРЕТЕНИЯ К ПАТЕНТУ (52) СПК C06B 49/00 (2019.05) (21)(22) Заявка: 2018131394, 11.08.2017 (24) Дата начала отсчета срока действия патента: Дата регистрации: Приоритет(ы): (30) Конвенционный приоритет: 12.08.2016 CN 201610665880.3 (43) Дата публикации заявки: 02.03.2020 Бюл. № 7 (45) Опубликовано: 02.07.2020 Бюл. № 19 (85) Дата начала рассмотрения заявки PCT на национальной фазе: 31.08.2018 CN 2017/097136 (11.08.2017) (87) Публикация заявки PCT: R U 2 7 2 5 4 2 4 WO 2018/028685 (15.02.2018) Адрес для переписки: 107061, Москва, ул. Преображенская пл., 6, ООО "Вахнина и Партнеры" (54) ПРИМЕНЕНИЕ СОЕДИНЕНИЙ В КАЧЕСТВЕ ЭНЕРГЕТИЧЕСКИХ МАТЕРИАЛОВ (57) Реферат: Изобретение относится к области эффективностью мгновенного высвобождения энергетических соединений, и в частности энергии при детонации. Трехмерная структура относится к использованию соединения, позволяет соединению не только иметь эффект имеющего кристаллическую структуру типа энергетического материала, но также перовскита АВХ3, как энергетического преодолевать недостатки существующих энергетических материалов. Высокая материала. Структурные характеристики стабильность такого ...

Use of the type of compound as an energy-containing material

본 발명은 에너지-함유 화합물의 분야에 속한다. 구체적으로, 본 발명은 에너지-함유 물질로서의 페로브스카이트형 화합물 ABX 3 의 용도에 관한 것이다. 본 발명의 발견으로서, 페로브스카이트의 구조적 특징은 이러한 유형의 화합물이 높은 안정성을 갖고, 따라서 종래 기술에 있어서 안정성이 불량한 폭발물에 의해 초래되는 안정성 문제를 극복한다; 동시에 상기 화합물은 에너지-함유 기가 풍부하고, 또한 이러한 산화성 에너지-함유 음이온과 환원성 유기 양이온이 공간적으로 이격되어 정렬되는 특징으로 인해, 그 구조 특징은 이러한 유형의 화합물이 우수한 순간 에너지를 갖게 한다. 결과물인 3 차원 구조는 상기 화합물이 에너지-함유 물질이 되게 할 뿐만 아니라, 일부 종래의 에너지-함유 물질에서의 단점을 극복할 수 있게 한다. The present invention belongs to the field of energy-containing compounds. In particular, the present invention relates to the use of perovskite like compound ABX 3 as energy-containing material. As a finding of the present invention, the structural characteristics of the perovskite overcome the stability problem caused by explosives of this type of compound having high stability and thus poor stability in the prior art; At the same time, the compound is rich in energy-containing groups, and also due to the feature that these oxidative energy-containing anions and the reducing organic cations are spatially spaced apart, their structural features make this type of compound have excellent instantaneous energy. The resulting three-dimensional structure not only makes the compound an energy-containing material, but also overcomes the shortcomings in some conventional energy-containing materials.

It is a kind of for N- beta-hydroxyethyl ethylenediamine synthesizing piperazine and catalyst of N methyl piperazine and preparation method thereof

本发明公开了一种用于N‑β‑羟乙基乙二胺合成哌嗪与N‑甲基哌嗪的催化剂及其制备方法，所述催化剂的载体为碱活化膨润土，活性物质的组成为X a Y b Z c O d ；其中X为Ni、Cu、Fe、Cr和Zn元素中的一种，Y为P、S、B元素的一种，Z为稀土元素中的一种，O为氧元素；a＝1，b＝0.2～2，c＝0.3～2，d值取决于a、b、c；本发明催化剂用于N‑β‑羟乙基乙二胺合成哌嗪与N‑甲基哌嗪，显著提高了N‑β‑羟乙基乙二胺的转化率和成哌嗪与N‑甲基哌嗪的总选择性，本发明催化剂载体价格便宜，催化剂制备简便，催化合成产物收率高，哌嗪与N‑甲基哌嗪的选择性可灵活调节以适应市场需求。

Bicyclo-substituted pyrazolone-azo derivative salt, process for its production and use thereof

一般式（Ｉ）で表されるビシクロ置換ピラゾロン−アゾ誘導体の製薬学的に許容される塩、その製造方法、それを含有する医薬組成物、及び治療薬としての、特にトロンボポエチン（TPO）模倣薬及びトロンボポエチン受容体アゴニストとしてのその使用に関する。一般式（Ｉ）の置換基の定義は、明細書において定義されたものと同一である。 【選択図】なし

Process for the production of amines

Verfahren zur Herstellung von Aminen durch Umsetzung von primären oder sekundären Alkoholen mit Stickstoffverbindungen, ausgewählt aus der Gruppe Ammoniak, primäre und sekundäre Amine, bei Temperaturen von 80 bis 250 DEG C und Drücken von 0,1 bis 40 MPa mit Wasserstoff in Gegenwart eines Katalysators, enthaltend Zirkonium, Kupfer, Cobalt und Nickel, dadurch gekennzeichnet, daß die katalytisch aktive Masse DOLLAR A 22 bis 40 Gew.-% sauerstoffhaltige Verbindungen des Zirkoniums, berechnet als ZrO¶2¶, DOLLAR A 1 bis 30 Gew.-% sauerstoffhaltige Verbindungen des Kupfers, berechnet als CuO, DOLLAR A 15 bis 50 Gew.-% sauerstoffhaltige Verbindungen des Nickels, berechnet als NiO, wobei das Molverhältnis von Nickel zu Kupfer größer 1 ist, DOLLAR A 15 bis 50 Gew.-% sauerstoffhaltige Verbindungen des Cobalts, berechnet als CoO, DOLLAR A 0 bis 10 Gew.-% sauerstoffhaltige Verbindungen des Aluminiums und/oder Mangans, berechnet als Al¶2¶O¶3¶ bzw. MnO¶2¶, DOLLAR A und keine sauerstoffhaltigen Verbindungen des Molybdäns enthält. Process for the preparation of amines by reacting primary or secondary alcohols with nitrogen compounds, selected from the group consisting of ammonia, primary and secondary amines, at temperatures from 80 to 250 ° C. and pressures from 0.1 to 40 MPa with hydrogen in the presence of a catalyst, containing zirconium, copper, cobalt and nickel, characterized in that the catalytically active composition DOLLAR A 22 to 40 wt .-% oxygen-containing compounds of zirconium, calculated as ZrO¶2¶, DOLLAR A 1 to 30 wt .-% oxygen-containing compounds of Copper, calculated as CuO, DOLLAR A 15 to 50% by weight of oxygen-containing compounds of nickel, calculated as NiO, the molar ratio of nickel to copper being greater than 1, DOLLAR A 15 to 50% by weight of oxygen-containing compounds of cobalt as CoO, DOLLAR A 0 to 10 wt .-% oxygen-containing compounds of aluminum and / or manganese, calculated as Al¶2¶O¶3¶ or MnO¶2¶, DOLLAR A and no oxygen contains compounds of ...

Catalyst and process for preparing an amine

A process for preparing an amine by reacting a primary or secondary alcohol, aldehyde and/or ketone with hydrogen and a nitrogen compound selected from the group of ammonia and primary and secondary amines, in the presence of a supported copper-, nickel- and cobalt-containing catalyst, wherein the catalytically active material of the catalyst, before the reduction thereof with hydrogen, comprises oxygen compounds of aluminum, of copper, of nickel and of cobalt, and in the range from 0.2 to 5.0% by weight of oxygen compounds of tin, calculated as SnO, and catalysts as defined above.

Catalyst and method for producing an amine

Process for the continuous production of an amine

Verfahren zur kontinuierlichen Herstellung eines Amins durch Umsetzung eines primären oder sekundären Alkohols, Aldehyds und/oder Ketons mit Wasserstoff und einer Stickstoffverbindung, ausgewählt aus der Gruppe Ammoniak, primäre und sekundäre Amine, bei einer Temperatur im Bereich von 60 bis 300 DEG C in Gegenwart eines kupferhaltigen Katalysators, wobei die katalytisch aktive Masse des Katalysators vor dessen Reduktion mit Wasserstoff DOLLAR A 20 bis 85 Gew.-% Aluminiumoxid (Al¶2¶O¶3¶), Zirkoniumdioxid (ZrO¶2¶), Titandioxid (TiO¶2¶) und/oder Siliziumdioxid (SiO¶2¶), DOLLAR A 1 bis 70 Gew.-% sauerstoffhaltige Verbindungen des Kupfers, berechnet als CuO, DOLLAR A 0 bis 50 Gew.-% sauerstoffhaltige Verbindungen des Magnesiums, berechnet als MgO, sauerstoffhaltige Verbindungen des Chroms, berechnet als Cr¶2¶O¶3¶, sauerstoffhaltige Verbindungen des Zinks, berechnet als ZnO, sauerstoffhaltige Verbindungen des Bariums, berechnet als BaO, und/oder sauerstoffhaltige Verbindungen des Calciums, berechnet als CaO, und DOLLAR A weniger als 30 Gew.-% sauerstoffhaltige Verbindungen des Nickels, berechnet als NiO, bezogen auf die sauerstoffhaltigen Verbindungen des Kupfers, berechnet als CuO, enthält und die Umsetzung in der Gasphase isotherm in einem Rohrreaktor erfolgt.

Salt of aryl propionic acid compound and pharmaceutical application thereof

本发明提供了一种式Ⅰ化合物的碱加成盐、盐的晶型、制备方法，以及包含这些盐的药物组合物、制剂形式和制药用途。式Ⅰ化合物是一种属于芳基丙酸类的药学活性物质，以其为基础制备了新颖的盐型及其结晶形式，在水溶解性、溶出度、稳定性方面均好于式Ⅰ化合物。这些盐型及其结晶形式具有给药剂量小、药物起效快以及可以减小毒副作用和提高生物利用度等优点。含有式Ⅰ化合物的碱加成盐的药物组合物在制备镇痛、解热、消炎药物中具有广泛用途和广阔前景。

Method for preparing styrene derivative

내용 없음

Synergistic compositions

本發明描述用於治療糖尿病(特別是非胰島素依賴型糖尿病(NIDDM)或第2型糖尿病)和糖尿病相關性病況的協同性組成物，其包含一或多種他汀類(statins)、或一或多種二肽醯肽酶IV(DPP IV)抑制劑、或一或多種雙胍抗高血糖劑、與如式(Ia)之PPAR促效劑，及適合用於這類方法的組成物。本發明也描述這類組成物之製備。本發明也關於如式(I)之某些新穎的PPAR促效劑的鹽類，製備這些新穎鹽類之方法及其用途。 □

PIPERAZINE CYANURATE AND POLYMERIC COMPOSITIONS INCLUDING THE SAME

Herbicide agent

The herbicide contains a compound of the formula I in which the individual substituents have the meaning given in Patent Claim 1. It has a broad spectrum of action against grass weeds and is tolerated by dicotyledon crop plants and various cereal species. <IMAGE>

ABSORBENT SOLUTION BASED ON N, N, N ', N'-TETRAMETHYL-1,6-HEXANEDIAMINE AND A SECONDARY DIAMINE OF THE ALKYLDIAMINE FAMILY AND METHOD FOR REMOVING ACIDIC COMPOUNDS FROM A GASEOUS EFFLUENT

L'invention concerne l'élimination de composés acides dans un effluent gazeux dans un procédé d'absorption mettant en œuvre une solution aqueuse de N,N,N',N'-Tétramethyl-1,6-hexanediamine formulée avec une diamine secondaire particulière, permettant d'obtenir une solution absorbante monophasique dans les conditions d'absorption des gaz acides tels que le CO2. L'invention s'applique avantageusement au traitement du gaz naturel et de gaz d'origine industrielle. The invention relates to the removal of acidic compounds in a gaseous effluent in an absorption process using an aqueous solution of N, N, N ', N'-Tetramethyl-1,6-hexanediamine formulated with a particular secondary diamine , making it possible to obtain a monophasic absorbent solution under the absorption conditions of acid gases such as CO2. The invention is advantageously applicable to the treatment of natural gas and gas of industrial origin.

New pyrrolidines and their preparation

Patent FR2178118A1

Thermodevelopable photosensitive material

Piperazine phenoxybutazone salts - as antiinflammatory agents having good gastric tolerance and low toxicity

Piperazine salts of pyrazolidinediones of formula (I) (where n=1 or 2) are antiinflammatory agents having good gastric tolerance and an LD50 (orally, mice) of 520+86 mg/kg.(I). are prepd by reacting in an aq. or aq/org. solvent, 4-butyl-2-phenyl-1-(p-hydroxy-pheny)-3,5-pyrazolidinedione and diethylenediamine (stoichiometric ratio of 1-2:1). Pref. solvents are methanol, ethanol etc.

Patent JPH0136462B2

ABSORBENT SOLUTION BASED ON N, N, N ', N'-TETRAMETHYL-1,6-HEXANEDIAMINE AND A SECONDARY DIAMINE OF THE ALKYLDIAMINE FAMILY AND METHOD FOR REMOVING ACIDIC COMPOUNDS FROM A GASEOUS EFFLUENT

NOVEL PHOSPHORUS ACID SALTS, COMPOSITIONS CONTAINING THEM AND THEIR APPLICATION AS FLAME RETARDANT

Patent FR2360253B1

Patent FR6978M

1,2-Diphenyl-4-(3-methyl-2-butenyl)-3,5-pyrazolidine dione salts - as analgesic, antiinflammatory and antirheumatic agents showing good gastric tolerance

Piperazine salts of pyrazolidinediones of formula (I) (where n=1 or 2) are antiinflammatory analgesic and antirheumatic agents showing good gastric tolerance and toxicity of LD50 (mice. orally)=3.65+0.28 mg/kg.

TOPICAL ANTI-INFLAMMATORY PHARMACEUTICAL COMPOSITIONS BASED ON CARBOXYLIC ACID SALTS, NEW CARBOXYLIC ACID SALTS AND THEIR PREPARATION

COMPOSITIONS PHARMACEUTIQUES TOPIQUES, UTILES NOTAMMENT EN TANT QUE MEDICAMENTS ANTI-INFLAMMATOIRES ETOU ANALGESIQUES, QUI CONTIENNENT EN TANT QUE SUBSTANCES ACTIVES DES SELS D'ACIDES CARBOXYLIQUES, EN PARTICULIER DES COMPOSES QUI REPONDENT A LA FORMULE: (CF DESSIN DANS BOPI) DANS LAQUELLE R, R, R, R ET R REPRESENTENT DES ATOMES D'HYDROGENE OU DES GROUPES HYDROCARBONES ALIPHATIQUES OU CYCLIQUES EVENTUELLEMENT SUBSTITUES DE NATURES VARIEES. CERTAINS DE CES COMPOSES SONT NOUVEAUX.

(O- (2,6-DICHLORANILINO)) -N-METHYL-D-GLUCAMMONIUM PHENYLACETATE, ITS OBTAINING AND PHARMACEUTICAL PREPARATIONS CONTAINING THE SAME

O-(2,6-DICHLORANILINO)-PHENYLACETATE DE N-METHYL-D-GLUCAMMONIUM. PREPARATION PHARMACEUTIQUE CONTENANT DU O-(2,6-DICHLORANILINO)-PHENYLACETATE DE N-METHYL-D-GLUCAMMONIUM OUTRE LES ADDITIFS PHARMACEUTIQUES HABITUELS. PREPARATION PHARMACEUTIQUE APPROPRIEE A L'ADMINISTRATION ORALE SELON LA REVENDICATION 2, CONTENANT D'ENVIRON 0,5 A ENVIRON 10 EN POIDS DE LA SUBSTANCE ACTIVE. N-METHYL-D-GLUCAMMONIUM O- (2,6-DICHLORANILINO) -PHENYLACETATE. PHARMACEUTICAL PREPARATION CONTAINING N-METHYL-D-GLUCAMMONIUM O- (2,6-DICHLORANILINO) -PHENYLACETATE IN ADDITION TO THE USUAL PHARMACEUTICAL ADDITIVES. PHARMACEUTICAL PREPARATION SUITABLE FOR ORAL ADMINISTRATION ACCORDING TO CLAIM 2, CONTAINING ABOUT 0.5 TO ABOUT 10 BY WEIGHT OF THE ACTIVE SUBSTANCE.

NOVEL CARBOXYLIC PHENYL ALIPHATIC ACID DERIVATIVES, PROCESS FOR THEIR PREPARATION AND THEIR USE AS MEDICAMENTS

LA PRESENTE DEMANDE DE BREVET A POUR OBJET LES PRODUITS DE FORMULE GENERALEI (CF DESSIN DANS BOPI) DANS LAQUELLE LES TROIS RADICAUX METHOXY SONT EN POSITION 3,4,5 OU 2,4,6 OU 2,4,5 OU 2,3,5 OU 2,3,6, ET DANS LAQUELLE, OU BIEN A ET B REPRESENTENT ENSEMBLE UNE DOUBLE LIAISON, OU BIEN A REPRESENTE UN ATOME D'HYDROGENE ET B REPRESENTE UN RADICAL HYDROXY, ET DANS LAQUELLE RH OU ALCOYL (C-C) SOUS LES DIFFERENTES FORMES STEREOISOMERES POSSIBLES, ET LES SELS ALCALINS, ALCALINO-TERREUX, OU D'AMINES DES PRODUITS DE FORMULE I DANS LAQUELLE R REPRESENTE UN ATOME D'HYDROGENE, UN PROCEDE POUR LEUR PREPARATION, ET LEUR APPLICATION COMME MEDICAMENTS. THIS PATENT APPLICATION IS FOR PRODUCTS OF GENERAL FORMULA (CF DRAWING IN BOPI) IN WHICH THE THREE METHOXY RADICALS ARE IN POSITION 3,4,5 OR 2,4,6 OR 2,4,5 OR 2,3, 5 OR 2,3,6, AND IN WHICH, OR A AND B TOGETHER REPRESENT A DOUBLE BOND, OR A REPRESENTS A HYDROGEN ATOM AND B REPRESENTS A RADICAL HYDROXY, AND IN WHICH RH OR ALCOYL (CC) UNDER THE VARIOUS POSSIBLE STEREOISOMERIC FORMS, AND ALKALINE, ALKALINO-EARTH, OR AMINE SALTS OF THE PRODUCTS OF FORMULA I IN WHICH R REPRESENTS A HYDROGEN ATOM, A PROCESS FOR THEIR PREPARATION, AND THEIR APPLICATION AS MEDICINAL PRODUCTS.

NOVEL DERIVATIVES OF CARBOXYLIC ALIPHATIC PHENYL ACIDS, PROCESS FOR THEIR PREPARATION AND THEIR APPLICATION AS MEDICAMENTS

Cation-anionic complexes of palladium

Изобретение относится к химии и медицине, а именно к новым катионно-анионным комплексам палладия. Комплексы содержат протонированный катион и полиядерный анион палладия. В качестве катионов используют протонированные метилморфолин [C 5 H 12 NO] + или 1-фенил-2-метиламинопропанол [C 10 H 16 NO] + , а в качестве анионов, соответственно - [PdCl 3 ] n 1- , где n - любое целое число, или [Pd 2 Cl 6 ] 2- . Новые полиядерные комплексы характеризуются низкой токсичностью и проявляют высокую противоопухолевую и радиопротекторную активность. 1 з.п. ф-лы, 2 ил., 6 табл., 3 пр. РОССИЙСКАЯ ФЕДЕРАЦИЯ (19) RU (11) (13) 2 699 809 C1 (51) МПК C07F 15/00 (2006.01) A61K 31/295 (2006.01) A61K 31/555 (2006.01) A61P 35/00 (2006.01) A61P 39/00 (2006.01) ФЕДЕРАЛЬНАЯ СЛУЖБА ПО ИНТЕЛЛЕКТУАЛЬНОЙ СОБСТВЕННОСТИ (12) ОПИСАНИЕ ИЗОБРЕТЕНИЯ К ПАТЕНТУ (52) СПК C07D 295/027 (2019.05); C07F 15/0066 (2019.05); A61K 31/295 (2019.05); A61K 31/555 (2019.05); A61P 35/00 (2019.05); A61P 39/00 (2019.05) (21)(22) Заявка: 2018134255, 27.09.2018 27.09.2018 Дата регистрации: 11.09.2019 (45) Опубликовано: 11.09.2019 Бюл. № 26 C 1 2 6 9 9 8 0 9 (54) Катионно - анионные комплексы палладия (57) Реферат: Изобретение относится к химии и медицине, а именно к новым катионно-анионным комплексам палладия. Комплексы содержат протонированный катион и полиядерный анион палладия. В качестве катионов используют протонированные метилморфолин [C5H12NO]+ R U или 1-фенил-2-метиламинопропанол [C10H16NO]+, а в качестве анионов, соответственно - [PdCl3]n1-, где n - любое целое число, или [Pd2Cl6]2-. Новые полиядерные комплексы характеризуются низкой токсичностью и проявляют высокую противоопухолевую и радиопротекторную активность. 1 з.п. ф-лы, 2 ил., 6 табл., 3 пр. (56) (продолжение): norbornene-evidence for the in situ formation of PdCl2 as the active species, Dalton Trans., 2003, p. 927-935. RU 2291872 C2, 20.01.2007. EA 10431 B1, 29.08.2008. RU 2613305 C2, 15.03.2017. Стр.: 1 C 1 (56) Список документов, цитированных в отчете о ...

Process for the preparation of an ethylene diamine or a heterocyclic compound containing nuclear nitrogen

Patent FR2260342B1

Reproduction layers for obtaining images by the action of heat

Sphingosine kinase inhibitors

Compuesto de fórmula**Fórmula** o una sal farmaceuticamente aceptable, hidrato o solvato del mismo, en la que: Y es -N(R4)-; R1 es fenilo, sustituido con 1 ó 2 halogenos, R2 es arilo, -alquilarilo, heterocicloalquilo, -alquil-heterocicloalquilo, heteroarilo o -alquil-heteroarilo opcionalmente sustituido; R3 es H, alquilo u oxo; en la que la parte de alquilo y anillo de cada uno de los grupos R2 y R3 anteriores esta opcionalmente sustituida con hasta 5 grupos que son independientemente alquilo (C1-C6), halógeno, haloalquilo, -0C(0)(alquilo C1-C6), -C(0)0(alquilo C1-C6), -CONR'R", -0C(0)NR' R", -NR'C(0)R", -CF3, -0CF3, -OH, alcoxilo hidroxialquilo, -CN, -CO2H, -SH, -S-alquilo, -SOR'R", -SO2R', -NO2 o NR'R", en la que R' y R" son independientemente H o alquilo (C1-C6), y en la que cada parte de alquilo de un sustituyente esta opcionalmente sustituida adicionalmente con 1, 2 1:5 3 grupos seleccionados independientemente de halógeno, CN, OH y NH2; y R4 es H o alquilo (C1-C6). Compound of formula ** Formula ** or a pharmaceutically acceptable salt, hydrate or solvate thereof, in which: Y is -N (R4) -; R1 is phenyl, substituted with 1 or 2 halogens, R2 is aryl, -alkylaryl, heterocycloalkyl, -alkyl-heterocycloalkyl, heteroaryl or -alkyl-heteroaryl optionally substituted; R3 is H, alkyl or oxo; wherein the alkyl and ring portion of each of the above R2 and R3 groups is optionally substituted with up to 5 groups that are independently (C1-C6) alkyl, halogen, haloalkyl, -0C (0) (C1-C6 alkyl ), -C (0) 0 (C1-C6 alkyl), -CONR'R ", -0C (0) NR 'R", -NR'C (0) R ", -CF3, -0CF3, -OH, hydroxyalkyl alkoxy, -CN, -CO2H, -SH, -S-alkyl, -SOR'R ", -SO2R ', -NO2 or NR'R", in which R' and R "are independently H or (C1 alkyl) -C6), and in which each alkyl part of a substituent is optionally further substituted with 1, 2 1: 5 3 groups independently selected from halogen, CN, OH and NH2; and R4 ...